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a b s t r a c t
Objective: This guideline summarizes the quality of the evidence to date and provides a
reasonable approach to the diagnosis, evaluation and treatment of the hypertensive disor-
ders of pregnancy (HDP).
Evidence: The literature reviewed included the previous Society of Obstetricians and
Gynaecologists of Canada (SOGC) HDP guidelines from 2008 and their reference lists,
and an update from 2006. Medline, Cochrane Database of Systematic Reviews (CDSR),
Cochrane Central Registry of Controlled Trials (CCRCT) and Database of Abstracts and
Reviews of Effects (DARE) were searched for literature published between January 2006
and March 2012. Articles were restricted to those published in French or English. Recom-
mendations were evaluated using the criteria of the Canadian Task Force on Preventive
Health Care and GRADE.
 2014 International Society for the Study of Hypertension in Pregnancy Published by
Elsevier B.V.
http://dx.doi.org/10.1016/j.preghy.2014.01.003
2210-7789  2014 International Society for the Study of Hypertension in Pregnancy Published by Elsevier B.V.
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Booking, ﬁrst antenatal visit, usually early in pregnancy; BP, blood pressure; CHEP, Canadian Hypertension Education Program; CHS, Canadian Hypertension
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elevated liver enzymes, low platelets; HBPM, home blood pressure monitoring; hCG, human chorionic gonadotropin; HDP, hypertensive disorders of
pregnancy; IM, intramuscular; IUGR, intrauterine growth restriction; IV, intravenous; LDH, lactate dehydrogenase; LMWH, low molecular weight heparin;
MgSO4, magnesium sulfate; mmHg, millimeters of mercury; NICE, National Institute for Health and Clinical Excellence; NICU, neonatal intensive care unit;
NNT, number needed to treat; NSAID, non-steroidal anti-inﬂammatory drug; po, per os; RCT, randomized controlled trial; RR, relative risk; SGA, small for
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Introduction
The hypertensive disorders of pregnancy (HDP) remain
leading causes of maternal and perinatal morbidity and
mortality [1,2]. This guideline summarizes the quality of
the relevant existing evidence and provides a reasonable ap-
proach o the diagnosis, evaluation, and treatment of theHDP.
Our purpose is to support evidence-based maternity
care of women who: are planning pregnancy and are at risk
of a HDP, have a HDP in the current pregnancy, or are post-
partum and had a HDP. When necessary, we have provided
expert opinion about reasonable clinical care. The informa-
tion should not be taken to dictate an exclusive course of
care, and is amenable to well-documented local amend-
ments. Our health intent and aim is, for pregnancies com-
plicated by a HDP, to improve short- and long-term
maternal, perinatal, and paediatric outcomes, and related
cost-effectiveness of interventions. The expected beneﬁt
of using this guideline is improved outcomes for mother,
baby, and child, through evidence-advised practice. The
target users are multidisciplinary maternity care providers
from primary to tertiary levels of health care.
The questions that this guideline seeks to address are:
 How, and in what setting, should blood pressure (BP) be
measured in pregnancy and what is an abnormal BP?
 How should proteinuria be measured in pregnancy?
What constitutes signiﬁcant proteinuria? Is heavy pro-
teinuria an indication for delivery?
 How should the HDP be diagnosed and classiﬁed? What
constitutes severe preeclampsia?
 What is the prognosis of pregnancies complicated by
pre-existing hypertension, gestational hypertension, or
preeclampsia?
 How can preeclampsia and its complications be pre-
dicted and/or prevented by lifestyle changes,medication
and/or care of a speciﬁc type or in a speciﬁc location?
 How shouldwomenwith a HDP bemanagedwith regard
to: initial investigations; dietary and lifestyle change;
place of care; antihypertensive therapy; aspects of
care speciﬁc to women with preeclampsia (such as
magnesium sulfate); mode and timing of delivery; intra-
partum care (including BP monitoring and analgesia/
anaesthesia); and postpartum monitoring, treatment,
and counselling regarding the impact of a HDP on both
future pregnancy outcomes and long-term maternal
and paediatric outcomes?
 What is the perspective of the patient with regard to
diagnosis and evaluation?
 How can this guideline be implemented into clinical
practice?
Methods
The guideline was developed by a methodologist and
maternity care providers (from obstetrics, internal medi-
cine, anaesthesia, and paediatrics) knowledgeable about
the HDP and guideline development.
The literature reviewed included the previous (2008)
SOGC HDP guideline and its references [3] covering articles
until July 2006, as well as updated literature from January
2006 until March 2012, using a search strategy similar to
that for the 2008 guideline (and available upon request);
a notable addition was exploration of the perspective and
interests of patients with a HDP [4]. Literature reviews
were conducted by librarians of the College of Physicians
and Surgeons of British Columbia and University of British
Columbia, restricting articles to those published in English
and French.
We prioritized randomized controlled trials (RCTs) and
systematic reviews (if available) for therapies and evaluated
substantive clinical outcomes for mothers (death; serious
morbidity, including eclampsia, HELLP syndrome, and other
major end-organ complications; severe hypertension;
placental abruption; preterm delivery; Caesarean delivery;
maternal adverse effects of drug therapies or other interven-
tions; and long-term health) and babies (perinatal death,
stillbirth, and neonatal death; small for gestational age in-
fants; NICU care; serious neonatalmorbidity, and long-term
paediatric health and neurodevelopment).
All authors graded the quality of the evidence and their
recommendations, using the Canadian Task Force on Pre-
ventive Health Care (Appendix Table A1) [5] and GRADE
(Level of evidence/Strength of recommendation, Appendix
Table A2) [6].
This document was reviewed by the Executive and
Council of the SOGC, and the approved recommendations
published on the SOGC website as an Executive Summary
(www.sogc.com).
Chapter 1: Diagnosis and classiﬁcation of the HDPs
Measurement of BP
Recommendations
1. BP should be measured with the woman in the sit-
ting position with the arm at the level of the heart
(II-2A; Low/Strong).
2. An appropriately sized cuff (i.e., length of 1.5 times
the circumference of the arm) should be used (II-2A;
Low/Strong).
3. Korotkoff phase V should be used to designate dia-
stolic BP (I-A; Moderate/Strong).
4. If BP is consistently higher in one arm, the arm with
the higher values should be used for all BP measure-
ments (III-B; Very low/Weak).
5. BP can be measured using a mercury sphygmoma-
nometer, calibrated aneroid device, or an automated
BP machine that has been validated for use in pre-
eclampsia (II-2A; Low/Strong).
6. Automated BP machines that have not been validated
for use in preeclampsia may under- or over-estimate
BP in those women and comparison of readings using
mercury sphygmomanometry or a calibrated aneroid
device is recommended (II-2A; Low/Strong).
7. In the ofﬁce setting, when BP elevation is non-severe
and preeclampsia is not suspected, either ambulatory
BPmonitoring (ABPM)orhomeBPmonitoring (HBPM)
is useful to conﬁrm persistently elevated BP (II-2C;
Very low/Weak).
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8. When HBPM is used, maternity care providers
should ensure that patients have adequate training
in measuring their BP and interpreting the readings
taken (III-C; Very low/Strong).
9. The accuracy of all BP measurement devices used in
hospitals or ofﬁces should be checked regularly
against a calibrated device (II-3C; Very low/Strong).
10. The accuracy of all automated devices used for
HBPM should be checked regularly against a cali-
brated device (III-C; Very low/Strong).
Comments
BP measurement in pregnancy should use non-preg-
nancy standardized technique [7,8]. BP may be measured
by ambulatory BP monitoring (ABPM) or home BPmonitor-
ing (HBPM) [9], using auscultatory or automated methods
[10]. Most clinics and hospitals use aneroid or automated
devices.
ABPM comprehensively measures BP, either in a com-
munity setting (serially over 24 h using an automated de-
vice) or by serial BP measurements in an obstetrical day
unit.
HBPM is done by the woman using an automated de-
vice, with duplicate measurements taken at least twice
daily over several days [7,11]. When HBPM values are nor-
mal but ofﬁce values elevated, ABPM or repeated HBPM are
recommended [7].
While pregnant women and practitioners prefer HBPM
to ABPM [12], pregnancy data are insufﬁcient to guide
choice. Patients require education about monitoring proce-
dures and interpretation of BP values, especially the
threshold for alerting maternity care providers.
A comprehensive list of approved devices for HBPM can
be found at http://www.dableducational.org, http://
www.bhsoc.org/default.stm, and http://www.hyperten-
sion.ca/devices-endorsed-by-hypertension-canada-dp1.
Women should use pregnancy- and preeclampsia-vali-
dated devices; if unavailable, clinicians should compare
contemporaneous HBPM and ofﬁce readings (see ‘Diagnosis
of Hypertension’).
Diagnosis of hypertension
Recommendations
1. The diagnosis of hypertension should be based on ofﬁce
or in-hospital BP measurements (II-B; Low/Strong).
2. Hypertension in pregnancy should be deﬁned as an
ofﬁce (or hospital) sBPP 140 mmHg and/or dBPP 90
mmHg, based on the average of at least two measure-
ments, taken at least 15 min apart, using the same
arm (II-2B; Low/Weak for sBP and Low/Strong for dBP).
3. ‘Resistant’ hypertension should be deﬁned as the need
for three antihypertensive medications for BP control
at P20 weeks’ gestation (IIIC; Low/Weak).
4. A ‘transient’ hypertensive effect should be deﬁned as
ofﬁce sBPP 140 mmHg or a dBPP 90mmHg which is
not conﬁrmed after rest, or on repeat measurement on
the same or on subsequent visits (II-2B; Very low/Weak).
5. A ‘white coat’ hypertensive effect refers to BP that is
elevated in the ofﬁce (i.e., sBPP 140 mmHg or dBPP
90 mmHg) but ABPM or HBPM sBP is <135 mmHg and
dBP is <85 mmHg (II-2B; Very low/Strong).
6. A ‘masked’ hypertensive effect refers to BP that is nor-
mal in the ofﬁce (i.e., sBP < 140 mmHg and dBP < 90
mmHg) but elevated by ABPM or HBPM (i.e.,
sBPP 135 mmHg or dBPP 85 mmHg) (II-2B; Very
low/Weak).
7. Severe hypertension should be deﬁned, in any setting,
as a sBP ofP160 mmHg or a dBP ofP110 mmHg based
on the average of at least two measurements, taken at
least 15 min apart, using the same arm (II-2B; Low/
Strong).
Comments
Hypertension in pregnancy is deﬁned by ofﬁce (or in-
hospital) sBPP 140 mmHg and/or dBPP 90 mmHg
[7,9,13]. We have recommended use of sBP and dBP to both
raise the proﬁle of sBP (given inadequate treatment of se-
vere systolic hypertension) and for consistency with other
international documents. We recommend repeat (ofﬁce or
community) BP measurement to exclude transient BP ele-
vation (see below).
Non-severely elevated BP should be conﬁrmed by re-
peat measurement, at least 15 min apart at that visit. BP
should be measured three times; the ﬁrst value is disre-
garded, and the average of the second and third taken as
the BP value for the visit [7]. Up to 70% of women with
an ofﬁce BP of P140/90 mmHg have normal BP on subse-
quent measurements on the same visit, or by ABPM or
HBPM [14–18]. The timing of reassessment should con-
sider that elevated ofﬁce BP may reﬂect a situational BP
rise, ‘white coat’ effect, or early preeclampsia [19,20].
Ofﬁce BP measurements may normalize on repeat mea-
surement, called ‘transient hypertension’. When BP is ele-
vated in the ofﬁce but normal in the community (i.e.,
daytime ABPM or average HBPM is <135/85 mmHg), this
is called ‘white coat’ effect [21–23]. When BP is normal
in the ofﬁce but elevated in the community, this is called
‘masked hypertension’ [24]. The difference in what is con-
sidered a normal BP in the ofﬁce (<140/90 mmHg) vs. in
the community (<135/85 mmHg) is important to note for
outpatient BP monitoring.
Severe hypertension as sBPP 160 mmHg (instead of
170 mmHg) reﬂects stroke risk [2,25].
Measurement of proteinuria
Recommendations
1. All pregnant women should be assessed for proteinuria
(II-2B; Low/Weak).
2. Urinary dipstick testing (by visual or automated test-
ing) may be used for screening for proteinuria when
the suspicion of preeclampsia is low (II-2B; Low/Weak).
3. Signiﬁcant proteinuria should be deﬁned asP0.3 g/d in
a complete 24-h urine collection or P30 mg/mmol uri-
nary creatinine in a spot (random) urine sample (II-2B;
Moderate/Strong).
4. Signiﬁcant proteinuria should be suspected when uri-
nary dipstick proteinuria is P1+ (II-2A; Moderate/
Strong).
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5. More deﬁnitive testing for proteinuria (by urinary pro-
tein:creatinine ratio or 24-h urine collection) is encour-
aged when there is a suspicion of preeclampsia,
including: P1+ dipstick proteinuria, in the setting of
hypertension with rising BP, or when BP is normal but
women have symptoms or signs suggestive of pre-
eclampsia (II-2A; Moderate/Strong).
6. Proteinuria testing does not need to be repeated once
the signiﬁcant proteinuria of preeclampsia has been
conﬁrmed (II-2A; Moderate/Strong).
7. There is insufﬁcient information to make a recommen-
dation about the accuracy of the urinary albumin:creat-
inine ratio (II-2 L; Low/Strong).
Comments
All pregnant women should be assessed for proteinuria
[26] in early pregnancy to detect pre-existing renal disease,
and at P20 weeks to screen for preeclampsia in those at
increased risk. Benign and transient causes should be con-
sidered (e.g., exercise-induced, orthostatic, or secondary
[e.g., UTI] proteinuria).
Proteinuria diagnosis can be performed on random
samples [by urinary dipstick, protein:creatinine ratio
(PrCr), or albumin:creatinine ratio (ACR)] or timed urine
collections (usually 24-h). Quantiﬁcation of urinary protein
by 24-h urine collection is often inaccurate [27], and has
been replaced by spot urine samples outside pregnancy
[28].
A dipstick value of 1+ proteinuria has low sensitivity
(55%, 95% CI 37–72%); a negative or ‘trace’ result should
not exclude further investigation if preeclampsia is sus-
pected [29]. Urinary dipstick testing has reasonable speci-
ﬁcity (84%, 95% CI 57–95%) for signiﬁcant proteinuria [29];
aP 1+ result should prompt additional investigations
(even with low suspicion of preeclampsia) and aP 2+ re-
sult strongly suggests 0.3 g/d. Whether automated dipstick
testing exhibits similar diagnostic test properties is not yet
clear [30,31].
A PrCr of P30 g/mol represents signiﬁcant proteinuria
in singleton pregnancy [32]; a threshold up to 40 g/mol
may be more appropriate in multiple pregnancy [33,34].
Outside pregnancy, early morning urine samples should
be tested as the most concentrated of the day [34–37].
ACR has published cut-offs of 2–8 mg/mmol for detec-
tion of 0.3 g/d proteinuria; it is not currently recom-
mended [30,38–42].
We suggest screening with urinary dipstick at each
antenatal visit. Proteinuria should be quantiﬁed (by PrCr
or 24 h urine collection) if preeclampsia is suspected (see
‘Investigations for classiﬁcation’).
Classiﬁcation of HDP
Recommendations
1. Hypertensive disorders of pregnancy should be classi-
ﬁed as pre-existing hypertension, gestational hyperten-
sion, preeclampsia, or ‘other hypertensive effects’ based
on different diagnostic and therapeutic considerations.
(II-2B; Low/Strong).
2. The presence or absence of preeclampsia must be ascer-
tained, given its clear association with more adverse
maternal and perinatal outcomes (II-2B; Low/Strong).
3. In women with pre-existing hypertension, preeclamp-
sia should be deﬁned as resistant hypertension, new
or worsening proteinuria, one or more adverse condi-
tions, or one or more severe complications (II-2B;
Low/Strong).
4. In women with gestational hypertension, preeclampsia
should be deﬁned as new-onset proteinuria, one or
more adverse conditions, or one or more severe compli-
cations (II-2B; Low/Strong).
5. Severe preeclampsia should be deﬁned as preeclampsia
complicated by one or more severe complications (II-
2B; Low/Strong).
6. Severe preeclampsia, as deﬁned in this guideline, war-
rants delivery (II-2B; Low/Strong).
7. The term PIH (pregnancy-induced hypertension) should
be abandoned, as its meaning in clinical practice is
unclear (III-D; Low/Strong).
Comments
The HDP are classiﬁed as pre-existing hypertension,
gestational hypertension, or preeclampsia among whom
‘other hypertensive effects’ can also be observed (Table 1)
(see Diagnosis of Hypertension). A ﬁnal diagnosis of HDP
type is made at 6 weeks postpartum.
Approximately 1% of pregnancies are complicated by
pre-existing hypertension, 5–6% by gestational hyperten-
sion, and 1–2% by preeclampsia; [43]. Rates of all are antic-
ipated to rise given older and more obese obstetric
populations with more antecedent medical complications.
For pre-existing and gestational hypertension, there are
two subgroups: (1) with comorbid conditions that man-
date tighter BP control as outside pregnancy (to protect
end-organ function) [7], and (2) with preeclampsia (given
its substantial maternal and perinatal risks).
We added a new category of ‘other hypertensive effects’
to raise awareness that ofﬁce BP that is not consistently
elevated may still be associated with elevated risks com-
pared with consistently normal BP.
Pre-existing (chronic) hypertension. This pre-dates preg-
nancy or appears before 20 weeks. Heightened risks of ad-
verse outcomes include: superimposed pre-eclampsia
(20%) [44–57], half of which develops at term
[46,47,52,54,58], preterm delivery (about 33%) [44–
50,52–54,56,57], abruption (1.8%), IUGR (15%) [44–52],
stillbirth (0.1% by 36 weeks [equivalent to risk at 41 weeks
in low risk pregnancies]), and NICU admission (up to 50%)
[54–59].
Gestational hypertension. This appears at P20 weeks. By
ABPM, 30% of women with hypertension at P20 weeks
demonstrate white coat effect (70% in third trimester)
[60]. Associated risks depend on gestational age at presen-
tation and progression to preeclampsia; gestational hyper-
tension at <34 weeks is associated with a 35% risk of
preeclampsia which takes an average of 5 weeks to
develop [61–66].
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Preeclampsia. This is the HDP associated with the greatest
risks, particularly when it is severe or present at
<34 weeks. The risk of SGA infants is primarily among wo-
men who present at <34 weeks, with macrosomia more
common with term preeclampsia [67].
s The pathogenesis of preeclampsia
Preeclampsia results from a mismatch between utero-
placental supply and fetal demands, leading to its systemic
inﬂammatory maternal (and fetal) manifestations (Fig. 1)
[68,69].
The most common maternal manifestations deﬁne pre-
eclampsia clinically: hypertension and proteinuria. Other
manifestations reﬂect end-organ dysfunction and are
non-speciﬁc. Stroke [2,25], and pulmonary oedema are
leading causes of maternal death in preeclampsia [25].
Jaundice is a late ﬁnding or may reﬂect another diagnosis
(e.g., acute fatty liver of pregnancy). Eclamptic seizures
are usually isolated [70–76].
Fetal manifestations may occur before, with, or in the
absence of maternal manifestations [77], and consist of oli-
gohydramnios, IUGR (up to 30%) [78], abnormal umbilical
artery Doppler velocimetry, decreased fetal middle cere-
bral artery resistance, an abnormal ductus venosus wave-
form, and/or stillbirth.
s Deﬁnition of preeclampsia
Preeclampsia is most commonly deﬁned by new-onset
proteinuria and potentially, other end-organ dysfunction.
Hypertension and proteinuria are discussed under ‘Diagno-
sis of hypertension’ and ‘Proteinuria’. Women with pre-
eclampsia may have a diminished or no nocturnal BP
decrease [10]. Table 2 outlines the end-organ dysfunction
of preeclampsia: ‘adverse conditions’ and ‘severe compli-
cations.’ ‘Adverse conditions’ consist of maternal symp-
toms, signs, and abnormal laboratory results, and
abnormal fetal monitoring results that may herald devel-
opment of severe maternal or fetal complications
(including stillbirth). The ‘adverse conditions’ are those
that wewait for and respond to (e.g., low oxygen saturation)
to avoid the severe complications that we wish to avoid
entirely (e.g., pulmonary oedema). That response could
be more intensive maternal or fetal monitoring, speciﬁc
treatment, or delivery. Severe maternal complications of
preeclampsia warrant delivery.
 The adverse conditions
These are preeclampsia manifestations that increase the
risk of adverse maternal or perinatal outcomes [87,95]
Table 2 lists the adverse conditions by maternal organ
Table 1
Classiﬁcation of the HDP.
Comments
Pre-existing (chronic) hypertension This is deﬁned as hypertension that was present either pre-pregnancy or that develops at <200 weeks
gestation
 With comorbid condition(s) Comorbid conditions (e.g., pre-gestational type I or II diabetes mellitus or kidney disease) warrant tighter BP
control outside of pregnancy because of their association with heightened cardiovascular risk
 With evidence of preeclampsia This is also known as ‘superimposed preeclampsia’ and is deﬁned by the development of one or more of the
following atP 20 weeks:
 Resistant hypertension, or
 New or worsening proteinuria, or
 One/more adverse condition(s)¥ or
 One/more severe complication(s)¥
Severe preeclampsia is deﬁned as preeclampsia with one or more severe complication(s)
Gestational hypertension This is deﬁned as hypertension that develops for the ﬁrst time atP 200 weeks’ gestation
 With comorbid condition(s) Comorbid conditions (e.g., pregestational type I or II diabetes mellitus or kidney disease) warrant tighter BP
control outside of pregnancy because of their association with heightened cardiovascular risk
 With evidence of preeclampsia Evidence of preeclampsia may appear many weeks after the onset of gestational hypertension.
Preeclampsia is deﬁned by gestational hypertension and one or more of the following:
 New proteinuria, or
 One/more adverse condition(s)¥ or
 One/more severe complication(s)¥
Severe preeclampsia is deﬁned as preeclampsia with one or more severe complication(s)
Preeclampsia Preeclampsia may arise de novo. It is deﬁned by gestational hypertension and one or more of the following:
 New proteinuria, or
 One/more adverse condition(s)¥ or
 One/more severe complication(s)¥
Severe preeclampsia is deﬁned as preeclampsia with one or more severe complications¥
’Other hypertensive effects’⁄
Transient hypertensive effect Elevated BP may be due to environmental stimuli or the pain of labour, for example
White coat hypertensive effect BP that is elevated in the ofﬁce (sBPP 140 mmHg or dBPP 90 mmHg) but is consistently normal outside of
the ofﬁce (<135/85 mmHg) by ABPM or HBPM
Masked hypertensive effect BP that is consistently normal in the ofﬁce (sBP < 140 mmHg or dBP < 90 mmHg) but is elevated outside of
the ofﬁce (P135/85 mmHg) by ABPM or repeated HBPM
ABPM, ambulatory BP monitoring; BP, blood pressure; HBPM, home BP monitoring.
* These may occur in women whose BP is elevated at <200 or P200 weeks who are suspected of having pre-existing or gestational hypertension/
preeclampsia, respectively.
¥ Please see Table 2 for deﬁnitions of adverse conditions and severe complications of preeclampsia.
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system. Of particular importance are: preterm preeclamp-
sia, chest pain or dyspnoea, or an abnormality of one/more
of: oxygen saturation by pulse oximetry, platelet count,
serum creatinine, or aspartate transaminase (AST)
[87,95]. Proteinuria predicts neither short-term adverse
outcomes nor long-term maternal renal prognosis
[88,89]. HELLP syndrome is represented by its component
parts; as we react to HELLP to prevent complications,
rather than seeking to avoid its occurrence.
How maternal adverse conditions may predict fetal or
neonatal outcomes in preeclampsia is unclear. The perina-
tal literature suggests that abnormal fetal monitoring of
various types may identify increased fetal risk. Abnormal-
ities in the NST should not be ascribed to antihypertensive
therapy [90]. Computerized NST improves perinatal out-
comes compared with visual interpretation in high risk
pregnancies [91]. Oligohydramnios was not predictive of
adverse outcome in observational studies of preterm pre-
eclampsia [92]. However, oligohydramnios and abnormal-
ities of Doppler velocimetry of the umbilicial artery have
been predictive of stillbirth [86]. The biophysical proﬁle
(BPP) has unproven utility in high risk women [67,93]
and BPP may falsely reassure with early-onset IUGR [94]
or preeclampsia [95].
Currently, there is no single fetal monitoring test to
accurately predict fetal compromise in women with pre-
eclampsia. Most experts suggest a combination of tests,
with emphasis on umbilical artery Doppler when there is
IUGR [67,96].
Other non-speciﬁc risk factors for severe complications
of preeclampsia are: immigrant status, young maternal
age, nulliparity, lower maternal weight, and in the index
pregnancy, multiple pregnancy and early-onset pre-
eclampsia [97].
 What is severe preeclampsia?
Deﬁnitions vary; most include multi-organ involve-
ment [3,98–100]. We modiﬁed our deﬁnition of severe pre-
eclampsia to be preeclampsia associated with a severe
Fig. 1. The origins and consequences of preeclampsia. In this model of the origins of preeclampsia, we describe preeclampsia that arises primarily due to
imperfect placentation (early-onset or ‘placental’ preeclampsia [pink]) and that arises due to either a lowered maternal threshold or excessive physiological
placentation (late-onset or ‘maternal’ preeclampsia [blue]). Some aspects of the preeclampsia process are speciﬁc to it, while others are shared with
normotensive intrauterine growth restriction. A lowered maternal threshold may inﬂuence the development of early-onset preeclampsia as well through
direct endothelial cell activation. The consequences of the endothelial cell activation that appears consistent between all women who develop preeclampsia
include a variable impact on multiple vulnerable organ systems. Disease severity generally correlates with the degree and number of organ dysfunctions.
ARDS: acute respiratory distress syndrome; AKI: acute kidney injury; ATN: acute tubular necrosis; DbM: diabetes mellitus; DIC: disseminated intravascular
coagulation; GCS: Glasgow Coma Scale; IUGR: intrauterine growth restriction; LV: left ventricular; PRES: posterior reversible encephalopathy syndrome;
RIND: reversible ischaemic neurological deﬁcit; SNP: single nucleotide polymorphism; TIA: transient ischaemic attack. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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complication(s). Severe preeclampsia now warrants
delivery regardless of gestational age. Our deﬁnition ex-
cludes heavy proteinuria and HELLP syndrome which is
not an absolute indication for delivery.
Other. A ‘transient’ hypertensive effect is not associated
with an increased risk of adverse outcomes.
White coat effect in early pregnancy (30%) is common
[19]. Forty percent of women progress to persistent hyper-
tension at P20 weeks (i.e., gestational hypertension) and
8% to preeclampsia. Women with ‘white coat’ effect have
risks (e.g., severe hypertension, preterm delivery, and NICU
admission) intermediate between normotension and
either pre-existing or gestational hypertension [15,60,66,
101–103].
Masked hypertension in early pregnancy (30%) is also
common [19], but associated perinatal risks are unknown.
Outcomes with masked hypertension at P20 weeks
(10%) equate to gestational hypertension [104,105].
Masked hypertension could be considered (and ABPM/
HBPM performed) if there are unexplained maternal or
perinatal complications typically associated with the HDPs.
Investigations to classify HDP
Recommendations
1. For women with pre-existing hypertension, the follow-
ing should be performed in early pregnancy (if not
previously documented): serum creatinine, fasting
blood glucose, serum potassium, and urinalysis (III-D;
Low/Weak) and EKG (II-2C; Low/Weak).
2. Among women with pre-existing hypertension or those
with a strong clinical risk marker for preeclampsia,
additional baseline laboratory testing may be based
on other considerations deemed important by health
care providers. (III-C; Very low/Weak).
3. Women with suspected preeclampsia should undergo
the maternal laboratory (II-2B; Moderate/Strong) and
pertinent fetal (II-1B; Moderate/Strong) testing
described in (Table 3).
4. Doppler velocimetry-based assessment of the fetal cir-
culation may be useful to support a placental origin
for hypertension, proteinuria, and/or adverse conditions
(including IUGR) (II-2B; Moderate/Weak) and for timing
of delivery (IA; High/Strong).
5. There is insufﬁcient evidence to recommend use of the
biophysical proﬁle (BPP) as part of a schedule of fetal
testing in women with a HDP (II-2I; Moderate/Weak).
6. If initial testing is reassuring, maternal and fetal testing
should be repeated if there is ongoing concern about
preeclampsia (e.g., change in maternal and/or fetal con-
dition) (III-C; Low/Weak).
Comments
Pre-existing hypertension. More than 95% of these women
have essential hypertension. We support the Canadian
Hypertension Education Program (CHEP) work-up (see
Table 2
Adverse conditions and severe complications of preeclampsia.
Organ system
affected
Adverse conditions (that increase the risk
of severe complications)
Severe complications (that warrant delivery)
CNS s Headache/visual symptoms s Eclampsia
s PRES
s Cortical blindness or retinal detachment
s Glasgow coma scale < 13
s Stroke, TIA, or RIND
Cardiorespiratory s Chest pain/dyspnoea
s Oxygen saturation < 97% [79]
s Uncontrolled severe hypertension (over a period of 12hr despite use of three
antihypertensive agents),
s Oxygen saturation < 90%, need forP 50% oxygen for > 1hr, intubation (other
than for Caesarean section), pulmonary oedema
s Positive inotropic support
s Myocardial ischaemia or infarction
Haematological s Elevated WBC count
s Elevated INR or aPTT [80]
s Low platelet count
s Platelet count < 50x109/L
s Transfusion of any blood product
Renal s Elevated serum creatinine [81]
s Elevated serum uric acid
s Acute kidney injury (creatinine > 150 lM with no prior renal disease)
s New indication for dialysis
Hepatic s Nausea or vomiting
s RUQ or epigastric pain
s Elevated serum AST, ALT, LDH, or
bilirubin
s Low plasma albumin [82]
s Hepatic dysfunction (INR > 2 in absence of DIC or warfarin)
s Hepatic haematoma or rupture
Feto-placental s Non-reassuring FHR
s IUGR [83,84]
s Oligohydramnios
s Absent or reversed end-diastolic ﬂow
by Doppler velocimetry
s Abruption with evidence of maternal or fetal compromise
s Reverse ductus venosus A wave [85,86]
s Stillbirth
AST, aspartate aminotransferase; ALT, alanine aminotransferase; DIC, disseminated intravascular coagulation; FHR, fetal heart rate; LDH, lactate dehy-
drogenase; PRES, posterior reversible leukoencephalopathy syndrome; RIND, reversible neurological deﬁcit < 48hr; RUQ, right upper quadrant; TIA, tran-
sient ischaemic attack.
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Table 3
Investigations to diagnosis or monitor women with a HDP.
Investigations for diagnosis Description in women with preeclampsia Description in women with other conditions
Maternal testing
Urine testing
Urinalysis (routine and
microscopy with/without
additional tests for
proteinuria)
Proteinuria (as discussed under Proteinuria)
without RBCs or casts
Haemoglobinuria (dipstick ‘haematuria’ without RBCs):
haemolytic anaemia
RBCs alone: renal stones, renal cortical necrosis (also associated
with back pain and oliguria/anuria)
RBCs and/or casts are associated with other glomerular disease
and scleroderma renal crisis and (about half of) TTP-HUS
Bacteria: UTI or asymptomatic bacteriuria
Proteinuria is usually absent in secondary causes of
hypertension such as pheochromocytoma,
hyperaldosteronism, thyrotoxicosis, coarctation of the aorta,
and withdrawal syndromes
Oxygen saturation
Pulse oximetry SpO2 < 97% associated with a heightened risk
of severe complications (including non-
respiratory)
May be decreased in any cardiorespiratory complication (e.g.,
pulmonary embolism)
CBC and blood ﬁlm
Haemoglobin " due to intravascular volume depletion " due to volume depletion from any cause (e.g., vomiting)
; if microangiopathic haemolysis (with HELLP) ; if microangiopathic haemolysis from other cause
; with any chronic anaemia (nutritional or myelodysplasia)
; with acute bleeding of any cause
WBC and differential M " due to neutrophilia of normal pregnancy
" with inﬂammation/infection
" with corticosteroids
Platelet count ; – associated with adverse maternal outcome) ; with gestational, immune (ITP), or thrombotic
thrombocytopoenia (TTP), APS, AFLP, myelodysplasia
Blood ﬁlm RBC fragmentation Microangiopathy due to mechanical causes (e.g., cardiac
valvopathy, cavernous haemangioma), DIC or other disorders of
endothelial function (e.g., APS, TTP-HUS, vasculitis, malignant
hypertension)
Tests of coagulation*
INR and aPTT " with DIC which is usually associated with
placental abruption – " is associated with
adverse maternal outcome
May be " in APS, DIC from other causes including sepsis,
amniotic ﬂuid embolism, stillbirth, massive haemorrhage,
haemangiomas, shock
" is prominent in AFLP
Fibrinogen M ; with all causes of DIC including massive haemorrhage,
genetic disorders
; more profound with AFLP than with HELLP
Usually normal in TTP-HUS (ADAMTS13 vWF cleaving protein
may be moderately decreased in HELLP [109] but ADAMTS 13
antibody should be absent)
Serum chemistry
Serum creatinine " due to haemoconcentration and/or renal
failure – " associated with adverse maternal
outcome
" with other acute or chronic kidney disease
Renal failure prominent in malignant hypertension, TTP-HUS
(along with thrombocytopoenia), AFLP (along with liver
dysfunction)
Serum uric acid " – associated with adverse maternal and
perinatal outcomes
" with dehydration, medication (e.g., HCTZ), genetic causes
Glucose M ; with AFLP, insulin therapy
AST or ALT " – associated with adverse maternal outcome " with AFLP and other ‘PET imitators’ but to a lesser degree,
and usually normal in TTP-HUS
May be increased in other pregnancy-related conditions (e.g.,
intrahepatic cholestasis of pregnancy) or conditions not
associated with pregnancy (e.g., viral hepatitis or cholecystitis)
LDH "which may be prominent – the " is associated
with adverse maternal outcome
" with AFLP, intravascular haemolysis
" LDH/AST ratio (>22) with TTP-HUS [110]
Bilirubin " – unconjugated from haemolysis or
conjugated from liver dysfunction
(early) " in AFLP, " with haemolytic anaemia,, other liver
disease with dysfunction, genetic diseases
Albumin ; – associated with adverse maternal and
perinatal outcomes
; as negative acute phase reactant with acute severe illness,
malnutrition, nephrotic syndrome, crystalloid infusion
fetal testing Abnormalities are not speciﬁc to the cause of poor placentation and/or placental dysfunction
Uterine artery Doppler
velocimetry
Unilateral/bilateral notching, or elevated pulsatility index or resistance index may support a diagnosis of
placental insufﬁciency including preeclampsia
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CHEP guidelines [7]). Relevant baseline testing in early
pregnancy may be prudent with chronic conditions (e.g.,
non-alcoholic steatohepatitis) that may make subsequent
interpretation of end-organ dysfunction difﬁcult. Women
at high risk for preeclampsia should be assessed for base-
line proteinuria (e.g., spot PrCr) given the insensitivity of
dipstick testing. Fasting blood glucose P7 mM pre-preg-
nancy or P5.3 mM in pregnancy should prompt appropri-
ate investigation/referral [106,107]. An abnormal P wave in
lead V1 by EKG may increase risk for gestational hyperten-
sion or preeclampsia [108]. Echocardiography may be use-
ful with known/suspected left ventricular dysfunction or
heart failure [7]. Routine measurement of plasma lipids is
not advised.
When preeclampsia is suspected. Women with suspected
preeclampsia should undergo blood and urine testing (Ta-
ble 3) [112–118] designed to either: (i) detect end-organ
involvement that increases the risk of adverse outcomes,
(ii) detect adverse outcomes (e.g., acute renal failure), (iii)
evaluate the seriousness of adverse outcome (e.g., haemo-
globin with abruption), or (iv) explore important differen-
tial diagnoses. Information collected will inform timing of
delivery.
Most abnormalities of maternal and fetal testing are
non-speciﬁc. Interpretation relies on multiple (not single)
abnormalities. With ongoing suspicion of preeclampsia, a
change in maternal or fetal status should prompt repeat
testing. Abnormalities of Doppler-based assessment of
the uterine or fetal circulations warrant obstetric consulta-
tion as they reﬂect elevated risks of adverse outcomes and
results may inform timing of delivery [119–126]. Consulta-
tion may be practically limited to telephone. The BPP does
not improve, and may adversely affect, high risk pregnancy
outcomes [93,95].
Preeclampsia imitators share manifestations with pre-
eclampsia, but require different treatments (Table 4)
[127–131].
Biomarkers for the diagnosis of preeclampsia: Imminent
developments. A minority of women with preeclampsia
will have an unclear clinical diagnosis, in which case trans-
lational biomarkers may improve diagnostic accuracy.
Leading biomarkers reﬂect the angiogenic imbalance that,
although not speciﬁc to preeclampsia [132], may underlie
many of its maternal features (particularly with early-on-
set) [133,134]. Two platforms measuring placental growth
factor (PlGF) and soluble FMS-like tyrosine kinase-1
(sFlt-1), either singly (i.e., PlGF) or as a ratio (e.g., sFlt-1/
PlGF ratio) [134,135] are being licenced in North America.
Chapter 2: Prediction and prevention
Predicting preeclampsia
Recommendations
1. Women should be screened for clinical risk markers of
preeclampsia from early pregnancy (II-2 C; Low/
Strong).
2. Consultation with an obstetrician or an obstetric inter-
nist, by telephone if necessary, should be considered for
women with a history of previous preeclampsia or
another strong clinical marker of increased preeclamp-
sia risk, particularly multiple pregnancy, antiphospho-
lipid antibody syndrome, signiﬁcant proteinuria at
booking, or a pre-existing condition of hypertension,
diabetes mellitus, or renal disease (II-2 B; Very low/
Strong).
3. Screening using biomarkers or Doppler ultrasound
velocimetry of the uteroplacental circulation cannot
be recommended routinely at present for women at
low or increased risk of preeclampsia until such screen-
ing has been shown to improve pregnancy outcome (II-
2C; Very low/Weak).
Comments
Of the many risk markers for preeclampsia (Table 5)
[99,111,136–164], many are known at booking and in-
crease the risk of preeclampsia two- to fourfold [165].
The strongest of these are previous preeclampsia, anti-
phospholipid antibody syndrome, pre-existing medical
conditions, and multiple pregnancy (all bolded in Table 5).
For other risk markers, the strength of the association is
less well established, less consistent, or the marker be-
comes available in the second or third trimesters (see
below).
Table 3 (continued)
Investigations for diagnosis Description in women with preeclampsia Description in women with other conditions
Fetal monitoring Abnormal or atypical FHR tracing (e.g., decreased variability)
Deepest amniotic ﬂuid pocket Oligohydramnios associated with adverse perinatal outcomes [98]
Ultrasonographic assessment of
fetal growth
Usually intrauterine fetal growth restriction (typically asymmetrical but can be symmetrical if early and/or
severe)
Umbilical artery Doppler Increased resistance, absent or reversed end-diastolic ﬂow
Ductus venosus Doppler Increased resistance, especially absent or reversed ‘‘a’’ wave
Middle cerebral artery Doppler Cerebral redistribution (decreased resistance, or ‘‘brain sparing effect’’). May be lost in extreme cases prior to fetal
death
AFLP, acute fatty liver of pregnancy; APS, antiphopholipid antibody syndrome; CBC, complete blood count; DIC, disseminated intravascular coagulation;
FHR, fetal heart rate; HELLP, haemolysis, elevated liver enzyme, low platelet syndrome); TTP-HUS, thrombotic thrombocytopenic purpura – haemolytic
uraemic syndrome); PET, preeclampsia-eclampsia; SpO2, oxygen saturation; UTI, urinary tract infection); vWF, von Willebrand Factor.
 Abnormal uterine artery Doppler velocimetry is practically deﬁned at 22–24 weeks as bilateral notching with mean resistance index (RI) > 0.55 (i.e., >
50th centile), unilateral notching with mean RI > 0.65 (> 90th centile), or no notching with mean RI > 0.70 (>95th centile) [163].
* Tests of coagulation are recommended if there is thrombocytopoenia [80] or placental abruption.
 PET imitators’ include AFLP, catastrophic APS, TTP-HUS, malignant hypertension and scleroderma renal crisis.
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Previous preeclampsia. With prior preeclampsia (of any
type), the risk of recurrent preeclampsia in a subsequent
pregnancy varies widely (median 15%) [169–191], as does
‘‘severe’’ recurrent preeclampsia (median 15%) [170,175,
176,181,182,184,188,192–195]. Recurrence is more likely
when prior preeclampsia was: of early onset [184,188,
194], ‘‘severe’’ [169,187], or complicated by eclampsia
[192,193,196] or HELLP syndrome [176,177,182,188].
Higher BMI in prior preeclampsia increases the recurrence
risk [185]. The following traditional preeclampsia risk
markers for ﬁrst occurrence do not inﬂuence recurrence:
multiple gestation, change of partner, and long interpre-
gnancy interval) [179,184,197–199].
Women with prior preeclampsia are as likely to have
gestational hypertension (median 22%) as preeclampsia
(median 15%) in their next pregnancy. Women with prior
gestational hypertension are more likely to experience ges-
tational hypertension in their next pregnancy (median
21%) than preeclampsia (median 4%) [169,171–173].
Screening for preeclampsia (in women with or without a
history of a HDP). The strongest clinical markers of pre-
eclampsia risk identiﬁable at antenatal booking are recom-
mended for screening for preeclampsia in the community
[145]. Women can be offered subspecialty referral, and
must receive more frequent assessments, if they have
one strong risk factor (bolded in Table 5), or two or more
minor risk factors (Table 5).
Of nine clinical predictors of preeclampsia among
nulliparous women carrying singleton pregnancies, one is
protective (miscarriage at 610 weeks with same partner)
and eight increase risk (younger maternal age, higher
MAP, higher BMI, family history of preeclampsia or coro-
nary heart disease, woman with lower birthweight, vaginal
bleeding during early pregnancy, and short duration of
sexual relationship); half of women destined to develop
preeclampsia would be detected using the model [162].
First trimester uterine artery Doppler, shows promise
but needs further ‘real life’ evaluation [200].
Markers of preeclampsia risk that become available in
the second and third trimesters include measures of: pla-
cental perfusion, vascular resistance, and morphology
(e.g., mean maternal second trimester BP, 24-h ABPM,
Doppler); maternal cardiac output and systemic vascular
resistance; fetoplacental unit endocrinology [e.g., preg-
nancy-associated plasma protein-A (PAPP-A) in the ﬁrst
trimester, and alpha-fetoprotein, hCG, and inhibin-A in
the early second trimester]; maternal renal function (e.g.,
serum uric acid or microalbuminuria); maternal endothe-
lial function and endothelial–platelet interaction (e.g.,
platelet count, antiphospholipid antibodies, or homocyste-
ine); oxidative stress (e.g., serum lipids); and circulating
angiogenic factors [201–203].
Systematic reviews of primary studies have evaluated
clinically available biomarkers [163,164,204] and no single
clinical test reaches the ideal of P90% sensitivity for
preeclampsia prediction. Only uterine artery Doppler at
20–24 weeks has sensitivity >60% for detection of pre-
eclampsia, particularly when testing is performed: (i) in
women at increased risk of preeclampsia; (ii) during the
second trimester, and/or (iii) when predicting severe and
early preeclampsia. Women with abnormal velocimetry
could be considered for increased surveillance to detect
preeclampsia or other adverse placental outcomes. Uterine
artery Doppler should not be used in low risk women
[162,205].
It is unclear whether markers used for Down syndrome
screening are useful in isolation (or with uterine artery
Doppler) for preeclampsia prediction [206].
Thrombophilia screening is not recommended for
investigation of prior preeclampsia or other placental com-
plications, except if the woman satisﬁes the clinical criteria
for the antiphospholipid antibody syndrome [207,208].
As no single test predicts preeclampsia with sufﬁcient
accuracy to be clinically useful [209], interest has grown
in researching multivariable models that include clinical
and laboratory predictors available at booking and thereaf-
ter [166,209,210]. Clinicians should support clinics con-
ducting relevant prospective longitudinal studies.
Preventing preeclampsia and its complications
We have based our recommendations on both preven-
tion of preeclampsia and/or its associated complications.
Pregnant women have been classiﬁed as being at ‘low’
or ‘increased’ risk of preeclampsia, usually by the presence
of one or more risk markers as shown in Table 5 [see
Prediction].
Table 4
Preeclampsia imitators.
Pregnancy related Not pregnancy related
Preeclampsia/HELLP
syndrome
Acute fatty liver of
pregnancy
Malignant hypertension regardless of the cause
Secondary causes of hypertension when associated with end-organ involvement (e.g., renal disease, pheochromocytoma)
Disseminated intravascular coagulation (from any cause)
Thrombotic thrombocytopenic purpura
Haemolytic uraemic syndrome
Vasculitis or other systemic rheumatic condition (systemic lupus erythematous, scleroderma, cryoglobulinemia,
catastrophic antiphospholipids syndrome)
Sepsis
Medications
Cavernous hemangiomas
Malignancy
HELLP, Haemolysis, Elevated Liver enzyme, Low Platelet syndrome.
114 L.A. Magee et al. / Pregnancy Hypertension: An International Journal of Women’s Cardiovascular Health 4 (2014) 105–145
Preventative interventions may be best started before
16 weeks when most of the physiologic transformation of
uterine spiral arteries occurs. Such early intervention has
the greatest potential to decrease early forms of pre-
eclampsia [211].
Preventing preeclampsia and its complications in women at
low risk
Women at ‘low risk’ of preeclampsia have usually been
from unselected populations of nulliparous and multipa-
rous women.
Recommendations
1. Calcium supplementation (of at least 1 g/d, orally) is
recommended for women with low dietary intake of
calcium (<600 mg/d) (I-A; High/Strong).
2. The following are recommended for other established
beneﬁcial effects in pregnancy: abstention from alcohol
for prevention of fetal alcohol effects (II-2E; Low/
Strong), exercise for maintenance of ﬁtness (I-A; Mod-
erate/Strong), periconceptual use of a folate-containing
multivitamin for prevention of neural tube defects (I-A;
Moderate/Strong), and smoking cessation for preven-
tion of low birthweight and preterm birth (I-E; High/
Strong),
3. The following may be useful: periconceptual and ongo-
ing use of a folate-containing multivitamin (I-B; Low/
Weak), or exercise (II-2B; Very low/Weak).
4. The following are not recommended for preeclampsia
prevention, but may be useful for prevention of other
pregnancy complications: prostaglandin precursors (I-
C; Low/Weak). or supplementation with magnesium
(I-C; Low/Weak), or zinc (I-C; Low/Weak).
Table 5
Risk markers for preeclampsia.*
Demographics and family
history
Past medical or obstetric history Current pregnancy
First trimester Second or third trimester
Previous preeclampsia Multiple pregnancy
Anti-phospholipid antibody
syndrome
Pre-existing medical condition(s)
 Pre-existing hypertension or book-
ing diastolic BPP 90 mmHg
 Pre-existing renal disease or book-
ing proteinuria
 Pre-existing diabetes mellitus
Maternal age–P 40 years Lower maternal birthweight and/or
preterm delivery
Overweight/obesity Elevated BP (gestational
hypertension)
Family history of preeclampsia
(mother or sister)
Heritable thrombophilias First ongoing pregnancy Abnormal AFP, hCG, inhA or E3***
Family history of early-onset
cardiovascular disease
Increased pre-pregnancy triglycerides New partner Excessive weight gain in
pregnancy
Non-smoking Short duration of sexual
relationship with current partner
Infection during pregnancy (e.g.,
UTI, periodontal disease)
Cocaine and metamphetamine use Reproductive technologies** Abnormal uterine artery Doppler
IUGR
Previous miscarriage at 610 weeks
with same partner
Inter-pregnancy
intervalP 10 years
Investigational laboratory
markers#
Booking sBPP 130 mmHg, or
booking dBPP 80 mmHg
Vaginal bleeding in early
pregnancy
Gestational trophoblastic disease
Abnormal PAPP-A or free ßhCG
Investigational laboratory markers
AFP, alfafetoprotein; E3, oestriol; hCG, human chorionic gonadotropin; inhA, inhibin A; IUGR, intrauterine fetal growth restriction; MSS, maternal serum
screening; PAPP-A, pregnancy-associated plasma protein A; UTI, urinary tract infection.
–Maternal age was considered as a continuous variable in the SCOPE study [162].
* Women at increased risk (who should be considered for specialty referral) are those with one of the bolded factors, or two or more of the unbolded
markers [139].
** Subfertility and its treatment (especially the use of donor eggs, sperm and/or gametes), after correction for multiple gestations.
*** Decreased ﬁrst trimester PAPP-A (pregnancy-associated plasma protein A)65th centile [141], decreased ﬁrst or second trimester PlGF (placental growth
factor) [154–156], unexplained increased second trimester AFP (alphafetoprotein) [142–147], increased second trimester hCG [145–148], increased ﬁrst or
second trimester inhibin A [144,149–152], increased second trimester activin. [153]. Abnormal uterine artery Doppler velocimetry is practically deﬁned at
22–24 weeks as bilateral notching with mean resistance index (RI) > 0.55 (i.e., >50th centile), unilateral notching with mean RI > 0.65 (>90th centile), or no
notching with mean RI > 0.70 (>95th centile) [164].
 Elevated BP is deﬁned as dBPP 110 mmHg before 20 weeks, 2nd trimester mean arterial pressure of P85 mmHg, or a 2nd trimester sBPP 120 mmHg
[140] standardized cut-offs for 24-h ambulatory BP or home BP monitoring have not been established.
 Heritable thrombophilia includes Factor V Leiden gene mutation and Protein S deﬁciency.
# Investigational markers include, in the ﬁrst trimester: PAPP-A, PlGF, PP-13 [167,168], and in the second trimester: elevated sFlt-1/PlGF (soluble fms-like
tyrosine kinase, placental growth factor) [155–157], PAI-1/PAI-2 (plasminogen activator inhibitor) [157], von Willebrand factor, and leptin [154,157,158].
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5. The following are not recommended: dietary salt
restriction during pregnancy (I-D; Moderate/Strong),
calorie restriction during pregnancy for overweight
women (I-D; Moderate/Strong), low-dose aspirin (I-E;
Moderate/Weak), vitamins C and E (based on current
evidence) (I-E; High/Strong), or thiazide diuretics (I-E;
Moderate/Strong).
6. There is insufﬁcient evidence to make a recommenda-
tion about the following: a heart-healthy diet (II-2L;
Very low/Weak), workload or stress reduction (which
includes bedrest) (II-2L; Very low/Weak), supplementa-
tion with iron with/without folate (I-L; Low/Weak),
vitamin D (I-L; Very low/Weak), pyridoxine (I-L; Low/
Weak), or food rich in ﬂavonoids (I-L; Very low/Weak).
Comments
Abstention from alcohol. The effect of alcohol abstention on
the incidence of HDPs is unkown, although reduced con-
sumption reduces BP outside pregnancy [212]. There is
no proven safe level of alcohol consumption in pregnancy
[213].
Aspirin (low-dose). Low dose aspirin does not decrease pre-
eclampsia incidence in low risk nulliparous women (RR
0.93; 95% CI 0.81–1.08) [204,214–217], although ﬁrst tri-
mester aspirin initiation is untested in RCTs.
Calcium. Oral calcium supplementation (of at least 1 g/d)
decreases the incidence of preeclampsia (RR 0.45, 95% CI
0.31–0.65) and gestational hypertension (RR 0.71, 95% CI
0.57–0.89) [218,219]. Maternal death or serious morbidity
was reduced (RR 0.80; 95% CI 0.65–0.97) [220], more than
offsetting the possible increase in HELLP (RR 2.67, 95% CI
1.05–6.82); it is possible that the BP lowering effect of cal-
cium masks progression to HELLP [221]. The beneﬁts of
calcium are probably restricted to women with low cal-
cium intake (<600 mg/day) [219]; potential harms (e.g.,
osteoporosis during lactation) have not been excluded
[222]. An alternative to supplementation may be 3–4 dairy
servings/day (250–300 mg calcium/serving).
Dietary changes. Dietary salt restriction does not affect ges-
tational hypertension or preeclampsia incidence (RR 1.11;
95% CI 0.46–2.66) [223]. Heart healthy diets are untested.
Energy or protein restriction diets for overweight wo-
men or those with excessive pregnancy weight gain did
not decrease gestational hypertension or preeclampsia
incidence [224]. Starvation ketosis may adversely alter fe-
tal neurodevelopment [225].
Consuming milk-based probiotics may lower preeclamp-
sia risk (population-based cohort) [226]; no RCT was
identiﬁed.
One RCT found a signiﬁcant reduction of BP with daily
intake of high-cocoa-content chocolate from 11 to
13 weeks until delivery [227]. Two RCTs are studying the
impact of ﬂavanol-rich chocolate on endothelial function
and the risk of preeclampsia (ClinicalTrials.gov
NCT01659060), (ClinicalTrials.gov NCT01431443).
Folate-containing multivitamins. Periconceptual use of a
folate-containing multivitamin is recommended for all
women for primary prevention of neural tube and possibly
other anomalies [228]. Periconceptual and ongoing regular
use of multivitamins may prevent gestational hypertension
[229] and preeclampsia in women with a BMI < 25 kg/m2
[230].
Lifestyle changes. Moderate-intensity regular aerobic exer-
cise (vs. normal physical activity) during pregnancy did not
decrease preeclampsia or other adverse outcomes [231].
Although workload/stress reduction is a common obstetric
intervention, no relevant RCTs were identiﬁed that tested
the impact on preeclampsia incidence.
Micronutrients other than calcium. Using generally low
quality data, magnesium supplementation (primarily in
low risk women) did not affect HDP incidence, but did de-
crease preterm birth (RR 0.73, 95% CI 0.57–0.94), low birth-
weight (RR 0.67, 95% CI 0.46–0.96), and SGA infants (RR
0.70, 95% CI 0.53–0.93) [232].
Zinc supplementation (20–90 mg elemental zinc), pri-
marily in low income low risk women did not affect HDP
incidence, but did decrease preterm delivery (RR 0.86;
95% CI 0.76–0.97) [233].
Prostaglandin precursors. Marine and other oils (prosta-
glandin precursors) do not decrease preeclampsia risk in
mixed populations of low and high risk women (RR 0.86,
95% CI 0.59–1.27), but do decrease birth before 34 weeks
(RR 0.69, 95% CI 0.49–0.99) [234]. Increased dietary intake
of ﬁsh for marine oil consumption is not recommended be-
cause of concerns about heavy metals [235].
Smoking cessation. Smoking cessation is recommended to
decrease low birthweight (RR 0.81; 95% CI 0.70–0.94) and
preterm birth (RR 0.84; 95% CI 0.72–0.98) [236]. Nicotine
replacement therapy in pregnancy neither improves quit
rates in pregnancy nor alters adverse outcomes [237].
Thiazide diuretics. Thiazide diuretics do not decrease pre-
eclampsia (RR 0.68; 95% CI 0.45–1.03) or other substantive
outcomes [238].
Vitamins C and E. Vitamins C and E from the ﬁrst or early
second trimester may have actually increased preeclamp-
sia, preterm prelabour rupture of membranes, IUGR, and
perinatal death [239–241].
Vitamin D. Low levels of 25 hydroxy vitamin D have been
associated with an increase in preeclampsia and other ad-
verse placental outcomes. There is insufﬁcient evidence to
recommend supplemental vitamin D (above the recom-
mended daily allowance of 400–1000 IU/d) for preeclamp-
sia prevention or improving pregnancy outcome otherwise
[242].
Other interventions for which no recommendation can be
made. There is insufﬁcient (or no) evidence on the effect
on preeclampsia of supplementation with: iron (routinely,
or not, or routinely with/without folic acid) [243], pyridox-
ine [244], garlic, vitamin A, selenium, copper, or iodine.
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Preventing preeclampsia and its complications in women at
increased risk
Women at ‘increased risk’ of preeclampsia are most com-
monly identiﬁed by a personal or family history of a HDP,
chronic medical disease, and/or abnormal uterine artery
Doppler before 24 weeks. Combining clinical, biochemical,
and/or ultrasonographic risk markers may better identify
women at increased preeclampsia risk (see Prediction); how-
ever, no intervention trial has used such an approach to eval-
uate preventative therapy [167,168,245].
Recommendations
1. The following are recommended for prevention of
preeclampsia: low-dose aspirin (I-A; High/Strong) and
calcium supplementation (of at least 1 g/d) for women
with low calcium intake (I-A; High/Strong).
2. Aspirin should be: taken in a low dose (75–162 mg/d)
(III-B; Very low/Strong), administered at bedtime (I-B;
Moderate/Strong), initiated after diagnosis of preg-
nancy but before 16 weeks’ gestation (I-B; Low/Weak),
and considered for continuation until delivery
(I-C; Very low/Weak).
3. Prophylactic doses of LMWH may be discussed in
women with previous placental complications (includ-
ing preeclampsia) to prevent the recurrence of ‘severe’
or early-onset preeclampsia, preterm delivery, and/or
SGA infants (I-B; Moderate/Weak).
4. The following may be useful: L-arginine (I-B; Moderate/
Weak), increased rest at home in the third trimester
(I-C; Low/Weak), and reduction of workload or stress
(III-C; Very low/Weak).
5. The following may be useful for prevention of other
pregnancy complications: prostaglandin precursors
(I-B; Low/Weak), magnesium supplementation (I-C;
Low/Weak), and heparin to prevent venous thromboembo-
lic disease (I-B; Low/Weak).
6. The following are recommended for other established
beneﬁcial effects in pregnancy (as discussed for women
at low risk of preeclampsia): abstention from alcohol
(II-2E; Low/Strong), periconceptual use of a folate-
containing multivitamin (I-A; Moderate/Strong), and
smoking cessation (I-E; High/Strong).
7. The following are not recommended: calorie restriction
in overweight women during pregnancy (I-D; Low/
Weak), weight maintenance in obese women during
pregnancy (III-D; Very low/Weak), antihypertensive
therapy speciﬁcally to prevent preeclampsia (I-D;
Moderate/Strong), vitamins C and E (I-E; High/Strong).
8. There is insufﬁcient evidence to make a recommenda-
tion about the usefulness of the following: the heart-
healthy diet (III-L; Very low/Weak); exercise (I-L; Very
low/Weak); selenium (I-L; Very low/Weak); garlic
(I-L; Very low/Weak); zinc, pyridoxine, iron (with or
without folate), vitamin D, or multivitamins with/
without micronutrients (all III-L; all Very low/Weak).
Comments
Antihypertensive therapy. Antihypertensive therapy does
not prevent preeclampsia (RR 0.99; 95% CI 0.84–1.18) or
adverse outcomes, but halves the risk of severe hyperten-
sion (RR 0.52; 95% CI 0.41–0.64) [246–248]. It is unknown
whether this is outweighed by a negative impact on peri-
natal outcomes [61] (see Treatment, Antihypertensive
Therapy).
Aspirin (low dose). In women at increased risk of pre-
eclampsia, low-dose aspirin results in a small decrease
in: preeclampsia (RR 0.83; 95% CI 0.77–0.89; NNT 72;
95% CI 52–119), preterm delivery (RR 0.92, 95% CI 0.88–
0.97; NNT 72, 95% CI 52–119), SGA infants (RR 0.90, 95%
CI 0.83 to 0.98; NNT 114, 95% CI 64–625) and perinatal
death (RR 0.86, 95% CI 0.76–0.98; NNT 243; 95% CI 131–
1666) without increasing bleeding risk [249].
Aspirin neither increases nor decreases miscarriage risk
[250,251]. There is no evidence of teratogenicity [252] or
other short- or long-term adverse peadiatric effects.
Who should receive aspirin, in what dose, and when,
are unclear. Aspirin is more effective in decreasing pre-
eclampsia: (i) among high risk women (NNT 19, 95% CI
13–34), (ii) when initiated before 16 weeks [252–255],
(iii) at doses >80 mg/day [249,256–259]; and (iv) when ta-
ken at bedtime [260,261]. Adjusting dosage based on plate-
let function testing may improve aspirin effectiveness
[262]. Aspirin may be continued until delivery [263] (see
Anaesthesia and Fluid Administration).
Calcium. Oral calcium supplementation (of at least 1 g/d)
decreases rates of preeclampsia (RR 0.22; 95% CI 0.12–
0.42), gestational hypertension (RR 0.47, 95% CI 0.22–
0.97) and preterm delivery (RR 0.45; 95% CI 0.24–0.83)
[218]. Three trials were conducted in low calcium intake
populations but no trial included women with prior pre-
eclampsia or reported on HELLP.
Dietary changes. No trials were identiﬁed of dietary salt
restriction on preeclampsia incidence. Women with pre-
existing hypertension following a DASH (Dietary Ap-
proaches to Stop Hypertension) diet may continue it. Heart
healthy diets are untested.
Dietary counselling to curb the rate of weight gain of
overweight pregnant women has no impact on gestational
hypertension or preeclampsia [224]. Pre-pregnancy or
early pregnancy weight reduction is untested [225].
Folate-containing multivitamin. Periconceptual (to prevent
neural tube defects and possibly, other anomalies) and
ongoing regular use of multivitamins is associated with
higher birthweights [264]. The Canadian FACT Trial for pre-
eclampsia prevention is recruiting (http://clinicaltri-
als.gov/show/NCT01355159).
Heparin. Prophylactic doses of any heparin (vs. no treat-
ment), decreases perinatal mortality (2.9% vs. 8.6%; RR
0.40, 95% CI 0.20–0.78), delivery <34 weeks (8.9% vs.
19.4%; RR 0.46, 95% CI 0.29–0.73), and SGA infants (7.6%
vs. 19.0%; RR 0.41, 95% CI 0.27–0.61) in women at high risk
of placentally mediated complications [265]. LMWH alone
(vs. no treatment) reduces the risk of: ‘severe’ or early-on-
set preeclampsia (1.7% vs. 13.4%; RR 0.16, 95% CI 0.07–
0.36), preterm delivery (32.1% vs. 47.7%; RR 0.77, 95% CI
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0.62–0.96), and SGA infants (10.1% vs. 29.4%; RR 0.42, 95%
CI 0.29–0.59), without a signiﬁcant effect on perinatal mor-
tality (pregnancy loss >20 weeks 1.9% vs. 5.3%; RR 0.41,
95% CI 0.17–1.02) [266]. Observed decreases in preeclamp-
sia and a composite of placentally-mediated pregnancy
complications (i.e., preeclampsia, placental abruption,
SGA infants, or fetal loss >12 weeks) (18.7% vs. 42.9%; RR
0.52, 95% CI 0.32–0.86) were more different than could
be expected by chance alone. Pending deﬁnitive data,
LMWH for preeclampsia prevention should be used
cautiously. The independent role of concomitant aspirin
needs clariﬁcation.
LMWH in prophylactic doses is associated with minimal
maternal and, theoretically, no fetal risks as it does not cross
the placenta. Major allergic reactions are uncommon (1.2%)
and no studied woman developed heparin-induced throm-
bocytopoenia. Prophylactic LMWH was rarely associated
with antenatal bleeding (0.42%), intrapartum bleeding
(0.92%), or wound haematoma after either Caesarean or
vaginal delivery (0.65%) [267], as observed in an audit of
tinzaparin use in pregnancy [268]. LMWH could be stopped
at 34–36 weeks to avoid intrapartum and postpartum risk.
If LMWH were effective for prevention of placental
complications, the incremental cost of preventing one case
of severe preeclampsia or a SGA infant approximates
$54.00 [269].
L-Arginine. L-Arginine given to women with gestational
hypertension, preeclampsia, or IUGR may lead to improved
maternal BP and uteroplacental circulation [270–275] but
dosage needs to be deﬁned and large RCTs are required.
Lifestyle changes. No impact of exercise was seen on gesta-
tional hypertension or preeclampsia [231]. Among seden-
tary women with prior preeclampsia speciﬁcally, walking
vs. stretching exercise did not alter pregnancy outcomes
[276]. There is one ongoing RCT of moderate intensity
exercise in women with prior preeclampsia [277].
RCT evidence is lacking for workload or stress reduction
to prevent preeclampsia.
Increased rest athome (30 min to6 h/day) in the third tri-
mester decreases preeclampsia incidence (RR 0.05; 95% CI
0.00–0.83 for increased rest alone; RR 0.13; 95% CI 0.03–
0.51 for rest plus nutritional supplement) [278]. The deﬁni-
tion of bed rest is unclear and compliance uncertain [279].
Treatment of periodontal disease does not decrease pre-
eclampsia [280,281].
Micronutrients other than calcium. Magnesium supplemen-
tation in a mixed low and high risk population did not de-
crease preeclampsia, but decreased preterm birth (RR 0.73;
95% CI 0.57–0.94), low birthweight (RR 0.67; 95% CI 0.46–
0.96), and SGA infants (RR 0.70, 95% CI 0.53–0.93) [232]. No
conclusions can be drawn because only one trial was of
high quality.
Selenium supplementation in the third trimester may or
may not decrease ‘‘gestational hypertension’’ (undeﬁned)
and preeclampsia [282,283].
Garlic has no impact on preeclampsia in women at in-
creased preeclampsia risk based on the historical positive
roll-over test [284].
Supplementation with CoQ10 from 20 weeks may re-
duce preeclampsia (RR 0.56, 95% CI 0.33–0.96) [285].
We did not identify relevant trials of zinc, pyridoxine,
iron (with/without folic acid), multivitamins with/without
micronutrients, vitamin A, vitamin D, iodine, or copper.
Prostaglandin precursors. Prostaglandin precursors do not
decrease preeclampsia in mixed low and high risk popula-
tions (RR 0.87; 95% CI 0.59–1.28) [234], but birth
<34 weeks is marginally decreased (RR 0.69; 95% CI 0.49–
0.99). Fish oil supplementation in women with previous
pregnancy complications showed more advanced gesta-
tional age at delivery in low and middle (but not high) ﬁsh
consumers [286].
Vitamins C and E. After contradictory pilot trial ﬁndings
[287–289], vitamins C and E do not decrease preeclampsia
risk; rather, they are more frequently associated with birth-
weight <2.5 kg and adverse perinatal outcomes [290–293].
Chapter 3: Treatment of the HDPs
Antenatal treatment
Non-pharmacological treatment of HDP
Dietary & lifestyle changes.
Recommendations
1. There is insufﬁcient evidence to make a recommenda-
tion about the usefulness of the following: new severe
dietary salt restriction for women with any HDP, ongo-
ing salt restriction among women with pre-existing
hypertension, heart-healthy diet, and calorie restriction
for obese women (all III-L; all Very low/Weak).
2. There is insufﬁcient evidence to make a recommenda-
tion about the usefulness of: exercise, workload reduc-
tion, or stress reduction (all III-L; all Very low/Weak).
3. For women with gestational hypertension (without pre-
eclampsia), some bed rest in hospital (vs. unrestricted
activity at home) may be useful to decrease severe
hypertension and preterm birth (I-B; Low/Weak).
4. For womenwith preeclampsia who are hospitalized, strict
bed rest is not recommended (I-D; Moderate/Weak).
5. For all other women with HDP, the evidence is insufﬁ-
cient to make a recommendation about the usefulness
of some bed rest, which may nevertheless, be advised
based on practical considerations (III-C; Low/Weak).
Comments
We lack RCT evidence examining the impact of the fol-
lowing on HDP outcomes: new severe dietary salt restric-
tion for women with any HDP, new or ongoing salt
restriction among women with pre-existing hypertension,
heart healthy diet, calorie restriction among overweight
women, or the impact of exercise. Preeclampsia is listed
as a contraindication to vigorous exercise in the relevant
SOGC 2003 Clinical Practice Guidelines [294].
No RCT data support workload reduction/cessation or
stress management (e.g. meditation) for any of the HDPs
when they are non-severe and outpatient-managed.
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Outside pregnancy, stress management by relaxation
techniques may improve BP control [7].
Bed rest is standard for women with a HDP [295,296].
Deﬁnitions have varied widely, compliance questioned
[279], and RCT data are limited. For preeclampsia, strict
(vs. some) bed rest in hospital does not alter outcomes
[297]. For gestational hypertension, some bed rest in hos-
pital (vs. routine activity at home) decreases severe hyper-
tension (RR 0.58; 95% CI 0.38–0.89) and preterm birth
(RR 0.53; 95% CI 0.29–0.99), although women prefer unre-
stricted activity at home [296]; whether beneﬁts are from
bed rest or hospitalization is not clear. In the absence of
clear beneﬁt, bed rest cannot be recommended due to
potential harmful physical, psychosocial, and ﬁnancial
effects [298,299].
We found no cost effectiveness studies of dietary and
lifestyle changes for HDP management.
The following recommendations apply to women with
either pre-existing or gestational hypertension.
Place of care
Recommendations
1. In-patient care should be provided for women with
severe hypertension or severe preeclampsia (II-2B;
Low/Strong).
2. A component of care through hospital day units (I-B;
Moderate/Strong) or home care (II-2B; Low/Strong)
can be considered for women with non-severe pre-
eclampsia or non-severe (pre-existing or gestational)
hypertension.
Comments
Out-of-hospital care for preeclampsia assumes that full
maternal and fetal assessments have been made and se-
vere disease excluded (see Classiﬁcation of HDP). Options
include obstetrical day units and home care. Eligibility de-
pends on home-to-facility distance, adequate maternal and
fetal surveillance, patient compliance, non-labile BP, and
absence of comorbid conditions or disease progression.
Hospital day units. Eligibility has varied from 30 to 60%
of women assessed [300,301]. Hospital admission and days
in hospital are reduced by day unit care, but outcomes and
costs are similar [301–304]. Women prefer out-of-hospital
care.
Home care. Eligibility is 625% [305]. Eligibility criteria
vary widely but include accurate BP self-measurement
(HBPM) [306], and consistency between home and hospital
BP [307].
In observational studies, home care has been variably
deﬁned in terms of activity levels, self- vs. nurse/midwife
assessments, and means of communication; [308,309] all
involved daily contact and a (usually) weekly outpatient
visit [305,308,309].
No RCTs have compared antepartum home care with
either hospital day or inpatient care. For gestational
hypertension, routine activity at home (vs. some bed rest
in hospital) is associated with more severe hypertension
(RR 1.72; 95% CI 1.12–2.63) and preterm birth (RR 1.89;
95% CI 1.01–3.45); women prefer routine activity at home
[310,311].
In observational studies of antepartum home care (vs.
inpatient care), hospital admission (25%) [309], re-admis-
sion (44%) [305] and maternal satisfaction rates [312] were
high, with similar outcomes for either gestational hyper-
tension [313], or mild preeclampsia [305]. Costs were low-
er with home care [309].
Antihypertensive therapy
For severe hypertension (BP of P160 mmHg systolic or
P110 mmHg diastolic)
Recommendations
1. BP should be lowered to <160 mmHg systolic and
<110 mmHg diastolic (I-A; Low/Strong).
2. Initial antihypertensive therapy in the hospital setting
should be with nifedipine short-acting (capsules) (I-A;
High/Strong), parenteral hydralazine (I-A; High/Strong),
or parenteral labetalol (I-A; High/Strong).
3. Alternative antihypertensive medications include a
nitroglycerin infusion (I-B; Moderate/Weak), oral meth-
yldopa (I-B; Very low/Weak), oral labetalol (I-B; Moder-
ate/Weak), oral clonidine (III-B; Low/Weak), or only
postpartum, oral captopril (III-B; Very low/Weak).
4. Refractory hypertension may be treated with sodium
nitroprusside (III-B; Low/Weak).
5. Nifedipine and MgSO4 can be used contemporaneously
(II-2B; Moderate/Weak)
6. MgSO4 is not recommended solely as an antihyperten-
sive agent. (I-E; High/Strong)
7. Continuous FHR monitoring is advised until BP is stable
(III-I; Very low/Weak).
Comments
BPP160/110 mmHg should be conﬁrmed after 15 min.
Most women will have preeclampsia, and were normten-
sive recently. These hypertensive events are ‘urgencies’
even without symptoms.
In the 2011 World Health Organization (WHO) pre-
eclampsia/eclampsia recommendations, antihypertensive
treatment of severe hypertension was strongly recom-
mended to decrease maternal morbidity and mortality
[100]. Severe systolic hypertension is an independent risk
factor for stroke in pregnancy [25]. Short-acting antihyper-
tensives successfully lower maternal BP in P80% of wo-
men in RCTs of one antihypertensive vs. another (see
below). Finally, the UK ‘Conﬁdential Enquiries into Maternal
Deaths’ identiﬁed failure to treat the severe (particularly
systolic) hypertension of preeclampsia as the single most
serious failing in the clinical care of women who died
[2,314].
A hypertensive ‘emergency’ is associated with end-
organ complications (e.g., eclampsia). Extrapolating from
outside pregnancy, hypertensive emergencies require
parenteral therapy (and arterial line) aimed at lowering
mean arterial BP by no more than 25% over minutes to
hours, and then further lowering BP to 160/100 mmHg
over hours. Hypertensive ‘urgencies’ are without end-organ
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complications andmay be treated with oral agents with peak
drug effects in 1–2 h (e.g., labetalol). Gastric emptying may
be delayed or unreliable during active labour.
Recommendations have been restricted to antihyper-
tensive therapy widely available in Canada. Most RCTs
have compared parenteral hydralazine, parenteral labeta-
lol, or calcium channel blockers (usually oral nifedipine).
All are reasonable (doses in Table 6), with selection guided
by associated medical conditions (e.g., asthma) or thera-
pies (e.g., current full dose labetalol). One agent sufﬁces
in at least 80% of women.
Parenteral hydralazine, compared with any other short-
acting antihypertensive, is associated with more adverse
effects, including maternal hypotension, Caesarean deliv-
ery, and adverse FHR effects [315]. Compared with calcium
channel blockers, hydralazine may be a less effective anti-
hypertensive and associated with more maternal side
effects [315–318]. Compared with parenteral labetalol,
hydralazine may be a more effective antihypertensive but
associated with more maternal hypotension and maternal
side effects [315,319,320]; however, labetalol is associated
with more neonatal bradycardia that may require inter-
vention [315,319,321].
Compared with oral nifedipine or parenteral nicardi-
pine, parenteral labetalol appears to be similarly effective
for BP control [322–324].
Oral labetalol (200 mg) has been used with good effect
within a regional pre-eclampsia protocol [325]. In a clinical
trial of preterm severe hypertension, 100 mg of oral labet-
alol every 6 h achieved the stated BP goal (of about 140/
90 mmHg) in 47% of women [326]. These data appear
insufﬁcient to support the UK recommendation to use oral
labetalol as initial therapy for severe pregnancy hyperten-
sion [99]; however, if severe hypertension is detected in
the ofﬁce setting, an oral antihypertensive may be useful
during transport to hospital for further evaluation and
treatment.
The nifedipine preparations appropriate for treatment
of severe hypertension are the capsule (bitten or
swallowed whole) and the PA tablet [327] which is not
currently available in Canada. The 5 mg (vs. 10 mg) capsule
may reduce the risk of a precipitous fall in BP [328]. The
risk of neuromuscular blockade (reversed with calcium
gluconate) with contemporaneous use of nifedipine and
MgSO4 is <1% [329,330].
MgSO4 is not an antihypertensive, having the potential
to lower BP transiently 30 min after a loading dose
[331–334].
Infused nitrogylcerin (vs. oral nifedipine) is comparably
effective without adverse effects [335–337]. Mini-dose
diazoxide (i.e., 15 mg IV every 3 min, vs. parenteral hydral-
zine) is associated with less persistent severe hypertension
[338].
For refractory hypertension in intensive care, higher
dose diazoxide can be considered (although there is more
hypotension than with labetalol) [339] as can sodium
nitroprusside (being mindful of the unproven risk of fetal
cyanide toxicity) [340].
Postpartum, hydralazine, labetalol, nifedipine, and
methyldopa are appropriate for treatment of severe hyper-
tension and during breastfeeding [341,342]. Oral captopril
is effective outside pregnancy [343] and is acceptable dur-
ing breastfeeding (http://toxnet.nlm.nih.gov/). Nitroglyc-
erin, sodium nitroprusside and diazoxide have not been
studied in breastfeeding. Oral clonidine has resulted in
high serum levels in breastfed infants (http://tox-
net.nlm.nih.gov/).
For non-severe hypertension (BP of 140–159/90–109 mmHg)
without comorbid conditions
Recommendations
1. Antihypertensive drug therapy may be used to keep sBP
at 130–155 mmHg and dBP at 80–105 mmHg (I-B; Low/
Weak).
2. The choice of antihypertensive agent for initial treat-
ment should be based on characteristics of the patient,
contraindications to a particular drug, and physician
and patient preference (III-C; Very low/Weak).
3. Initial therapy in pregnancy can be with one of a variety
of antihypertensive agents available in Canada: methyl-
dopa (I-A; High/Strong), labetalol (I-A; High/Strong),
other beta-blockers (acebutolol, metoprolol, pindolol,
and propranolol) (I-B; Moderate/Strong), and calcium
channel blockers (nifedipine) (I-A; High/Strong),
4. Angiotensin converting enzyme (ACE) inhibitors and
angiotensin receptor blockers (ARBs) should not be
used during pregnancy (II-2E; Moderate/Strong).
5. Atenolol and prazosin are not recommended prior to
delivery (I-D; Moderate/Weak).
For non-severe hypertension (BP of 140–159/90–109 mmHg)
with comorbid conditions
Recommendations
1. For women with comorbid conditions, antihypertensive
drug therapy should be used to keep sBP at <140 mmHg
and dBP at <90 mmHg (III-C; Low/Weak).
2. Initial therapy in pregnancy can be with one of a variety
of antihypertensive agents as listed for women without
co-morbidities (III-C; Very low/Weak).
3. Captopril, enalapril, or quinapril may be used postpar-
tum, even during breastfeeding (III-B; Low/Weak).
Comments
Management of non-severe pregnancy hypertension is
much debated. Any antihypertensive therapy will, com-
pared with placebo or no therapy: decrease transient se-
vere hypertension (RR 0.50; 95% CI 0.41–0.61) without a
difference in other outcomes, including preeclampsia or
preterm delivery [243]. However, antihypertensive lower-
ing of BP may reduce fetal growth velocity [61,247,248]);
not all subsequently published data are consistent with
this [344]. The deﬁnitive CHIPS (Control of Hypertension
In Pregnancy Study) RCT addressing the issue of BP targets
in non-severe hypertension will publish its results in 2014
[345]. No reliable long-term developmental outcome data
exist [346,347] (see Effect on long-term child development).
Women without comorbid conditions should receive
antihypertensives to lower dBP to 80–105 mmHg,
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recognizing that non-severe hypertension is not an abso-
lute indication for treatment outside pregnancy [7]. The
upper dBP acknowledges BP variability, BP measurement
inaccuracies, and the desire to avoid a dBPP 110 mmHg.
The lower dBP reﬂects concern around limiting uteropla-
cental perfusion [247,248], and recommendations outside
pregnancy [7].
In contrast, women with comorbid conditions (Ta-
ble 1) should probably have their BP lowered to <140/
90 mmHg. Lower limits for BP goals are unclear. Outside
pregnancy, <130/80 mmHg is speciﬁed only with diabetes
mellitus but to achieve risk reduction over a longer time-
frame [7,348].
CHEP recommendations provide initial guidance about
treatment of secondary causes of hypertension [7].
There is little to guide the choice of antihypertensives in
women with or without co-morbidities. Many antihyper-
tensives have been compared with placebo or no therapy:
methyldopa, labetalol, other pure beta-blockers (acebuto-
lol, mepindolol, metoprolol, pindolol, and propranolol),
calcium channel blockers (isradipine, nicardipine, nifedi-
pine, and verapamil), hydralazine, prazosin, and ketanserin
[246]; ketanserin, isradipine, nicardipine, and mepindolol
are not used in Canada.
In comparative trials (usually of beta-blockers vs. meth-
yldopa), beta-blockers (i.e., labetalol, pindolol, metoprolol,
or oxprenolol) were more effective antihypertensives than
methyldopa (RR 0.75; 95% CI 0.58–0.94), without other dif-
ferences in outcomes [246,347] (see ‘Aspects of care speciﬁc
to women with pre-existing hypertension’ and ‘Effects on
long-term child development’).
Be familiar with a number of antihypertensive options.
Only 30–50% of non-pregnant patients will respond to a gi-
ven antihypertensive, and monotherapy will be insufﬁcient
if BP is more than 20/10 mmHg above target. Women may
have a contraindication to a speciﬁc medication (e.g., se-
vere asthma and beta-blockers) or a characteristic that
makes an agent preferable (e.g., Black race and calcium
channel blockers).
There is no renoprotection agent that can replace ACE
inhibitors or ARBs for women with diabetes mellitus and
pre-pregnancy microalbuminuria; however, BP control is
both a critical element of ACE inhibitor renoprotection
and can be provided by other antihypertensives. Some
ACE inhibitors are acceptable during breastfeeding
(see ‘Severe Hypertension’).
Labetalol and methyldopa are the oral agents used most
frequently in Canada [350] (Table 7). ACE inhibitors and
ARBs are fetotoxic [351] (particularly nephrotoxic) [352].
Prazosin may cause stillbirths [353]. Atenolol (in contrast
with other cardioselective beta-blockers) may associated
with reduced fetal growth velocity [354–358], making
other agents preferable. Oral hydralazine monotherapy is
not recommended due to maternal side effects [359].
Thiazide diuretics can be used [238]. Oral antihyperten-
sives do not appear to change FHR or pattern; relevant
changes are best attributed to evolution of the underlying
HDP, not to the antihypertensive agent.
The cost-effectiveness of antihypertensives for severe or
non-severe hypertension is unknown.
Corticosteroids for acceleration of fetal pulmonary maturity
Recommendations
1. Antenatal corticosteroid therapy should be considered
for all women who present with preeclampsia at 6346
weeks gestation (I-A; High/Strong).
2. Antenatal corticosteroid therapy should be considered
for women who present at 6346 weeks with gestational
hypertension (despite the absence of proteinuria or
‘adverse conditions’) only if delivery is contemplated
within the next 7 days (III-L; Low/Weak).
3. A rescue dose of corticosteroids may be considered for
women at 6346 weeks who remain at high risk of pre-
term delivery 7 days or more after an initial course of
antenatal corticosteroids (I-C; Low/Weak).
4. Antenatal corticosteroids may be considered for women
delivered by elective Caesarean delivery at 6386 weeks’
gestation to reduce respiratory morbidity (I-B; Low/
Weak).
Comments
When administered at 6 346 weeks, antenatal cortico-
steroids accelerate fetal pulmonary maturity and decrease
neonatal mortality and morbidity, including women with
Table 6
The most commonly used agents for treatment of a BPP 160/110 mmHg.
Agent Dosage Onset Peak Duration Comments
Labetalol Start with 20 mg IV; repeat 20–80 mg
IV q 30 min, or 1–2 mg/min, max
300 mg (then switch to oral)
5 min 30 min 4 h Best avoided in women with asthma or heart failure.
Neonatology should be informed if the woman is in
labour, as parenteral labetalol may cause neonatal
bradycardia
Nifedipine 5–10 mg capsule to be swallowed, or
bitten then swallowed, every 30 min
5–10 min 30 min 6 h Staff should be aware of the distinction between short-
acting nifedipine capsules used for treatment of severe
hypertension, and both the intermediate-acting PA
tablets (that can be used for treatment of non-severe
or severe hypertension), and the slow-release tablets [XL]
that are used for non-severe hypertension
Hydralazine Start with 5 mg IV; repeat 5–10 mg IV
every 30 min, or 0.5–10 mg/hr IV, to a
maximum of 20 mg IV (or 30 mg IM)
5 min 30 min May increase the risk of maternal hypotension
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HDPs [360]. RCTs that administered steroids at 330 to
346 weeks resulted in reduced neonatal RDS [360], a sub-
ject of ongoing trials. The beneﬁcial effects of steroids
can be observed when the ﬁrst dose is administered as late
as within 4 h before birth. There is no evidence of short- or
long-term maternal or fetal adverse effects of a single
course of antenatal corticosteroids.
If expectantly managed, women with preeclampsia re-
mote from term (usually <340 weeks) will be delivered
within two weeks of corticosteroid administration, but
the duration of pregnancy prolongation varies from hours
to weeks. All eligible women with preeclampsia should
receive antenatal corticosteroids.
If women with preeclampsia remain pregnant seven or
more days after receipt of antenatal corticosteroids, there
is insufﬁcient information available to recommend another
course. Repeated dose antenatal corticosteroids are associ-
ated with short-term neonatal respiratory, without dem-
onstrated long-term, beneﬁts [361] and some concern
about harm [362].
One third of women with gestational hypertension at
<340 weeks will develop preeclampsia over an average of
5 weeks; delivery is unlikely within 7 days [65]. Clinicians
should administer corticosteroids to those women whom
they feel are at high risk of delivery within a week.
Antenatal corticosteroids may cause signiﬁcant, tran-
sient changes in FHR and variability up to 4 days after
administration [363–365].
Prior to elective Caesarean delivery at 6386 weeks,
antenatal corticosteroids decrease the excess neonatal
respiratory morbidity and NICU admissions [366,367]. All
subgroup analyses have not necessarily revealed such ben-
eﬁts following Caesarean or vaginal delivery [360].
No cost effectiveness data were identiﬁed for hyperten-
sive pregnant women.
Timing of delivery
Recommendations
Delivery is the only intervention that initiates resolu-
tion of preeclampsia, and women with gestational hyper-
tension or pre-existing hypertension may develop
preeclampsia.
Women with pre-eclampsia
1. Consultation with an obstetrician (by telephone if nec-
essary) is mandatory in women with severe preeclamp-
sia (III-B; Low/Strong).
2. All women with severe preeclampsia should be deliv-
ered immediately (either vaginally or by Caesarean),
regardless of gestational age (III-C; Low/Strong).
3. For women with non-severe preeclampsia at <240
weeks’ gestation, counselling should include as an
option, information about delivery within days (II-2B;
Low/Weak).
4. For women with non-severe preeclampsia at 240–336
weeks’ gestation, expectant management should be
considered, but only in perinatal centres capable of
caring for very preterm infants (I-B; Moderate/Weak).
5. For women with non-severe preeclampsia at 340–366
weeks’ gestation, there is insufﬁcient evidence to make
a recommendation about the beneﬁts or risks of expec-
tant management (III-L; Low/Weak).
6. For women with preeclampsia at P370 weeks’ gesta-
tion, immediate delivery is recommended (I-A; High/
Strong).
7. For women with non-severe preeclampsia complicated
by HELLP syndrome at 240–346 weeks’ gestation,
consider delaying delivery long enough to administer
antenatal corticosteroids for acceleration of fetal
pulmonary maturity if there is temporary improvement
in maternal laboratory testing (II-2B; Low/Weak).
8. All women with HELLP syndrome at P350 weeks’
gestation should be considered for immediate delivery
(II-2B; Moderate/Strong).
Women with gestational hypertension
1. For women with gestational hypertension (without pre-
eclampsia) at P370 weeks’ gestation, delivery within
days should be discussed (I-B; Low/Weak).
2. For women with gestational hypertension (without pre-
eclampsia) at <370 weeks’ gestation, there is insufﬁcient
evidence to make a recommendation about the beneﬁts
or risks of expectantmanagement (III-L;Very low/Weak).
Women with pre-existing hypertension
1. For women with uncomplicated pre-existing hyperten-
sion who are otherwise well at P370 weeks’ gestation,
delivery should be considered at 380–396 weeks’ gesta-
tion (II-1B; Low/Weak).
Comments
Preeclampsia. The Conﬁdential Enquiries into Maternal Death
have related underappreciation of risk in preeclampsia to
potentially avoidable complications. Subspecialty consul-
tation has been advised, by telephone if necessary, partic-
ularly for women with severe preeclampsia [314].
The phrase, ‘‘planned delivery on the best day in the
best way,’’ reﬂects the myriad of considerations regarding
timing (and mode) of delivery [325]. Timing delivery will
reﬂect evolving adverse conditions (Table 2). Consensus-
derived indications for delivery are: (i) term gestation,
(ii) development of severe maternal HDP-associated
Table 7
Doses of the most commonly used agents for treatment of a BP of 140–159/90–109 mmHg.
Agent Dosage Comments
Methyldopa 250–500 mg po bid-qid (max 2 g/d) There is no evidence to support a loading dose of methyldopa
Labetalol 100–400 mg po bid-tid (max
1200 mg/d)
Some experts recommend a starting dose of 200 mg po bid
Nifedipine XL preparation (20–60 mg po OD,
max 120 mg/d)
Ensure that the correct form of nifedipine has been prescribed so that the XL preparation is not
confused with the capsules
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complication(s) (Table 2) [92], (iii) stillbirth, or (iv) results
of fetal monitoring that indicate delivery according to
general obstetric practice [92,363,368]. Currently, no tool
exists to guide balancing risks, beneﬁts, and the
preferences of the woman and her family.
The best treatment for the mother is always delivery,
limiting her exposure to preeclampsia, so expectant
management is best considered when potential perinatal
beneﬁts are substantial, usually at early gestational ages.
Expectant management of preeclampsia refers to at-
tempted pregnancy prolongation following a period of
maternal and fetal observation and assessment, and mater-
nal stabilization. Following this, 40% will be considered
eligible for pregnancy prolongation [92]. Expectant
management should occur only in an experienced unit
where neonates can be cared for at the woman’s current
gestational age (as delivery cannot be accurately anticipated).
Expectant management at <240 weeks is associated
with perinatal mortality >80% and maternal complications
of 27–71% (including one maternal death) [368,369].
Termination of pregnancy should be discussed.
Expectant management at 240–336 weeks may decrease
neonatal respiratory distress syndrome, necrotizing
enterocolitis, and NICU care, despite poor fetal growth
velocity during the time gained [370,371]. Rates of serious
maternal complications appear very low (median < 5%)
[92]. Timing of delivery should be individualized, recogniz-
ing that on average, pregnancy prolongation is 2 weeks. If
preeclampsia is complicated by HELLP, fewer days will be
gained (median 5) and serious maternal morbidity will
be higher (median 15%); >50% have temporary improve-
ment of HELLP which may enable regional anaesthesia or
vaginal delivery [92].
For late preterm preeclampsia (340–366 weeks), delay-
ing delivery may facilitate cervical ripening and vaginal
delivery [372], but substantial perinatal beneﬁts are not
anticipated and there are concerns about the vulnerability
of the fetal brain to injury at this time [373]. We await data
from two RCTs (HYPITAT-II, www.studies-obsgyn.nl;
ClinicalTrials.gov NCT00789919). In antihypertensive com-
parison RCTs near or at term, pregnancy prolongation was
associated with a Caesarean delivery rate of 70% [374–
378], with little or no information about pregnancy prolon-
gation or other maternal or perinatal outcomes.
With term preeclamspia (370–420 weeks) labour induc-
tion is indicated to reduce poor maternal outcome (RR
0.61, 95% CI 0.45–0.82) [379]. This policy has a favourable
impact on health-related quality of life [380].
Gestational hypertension. Women with term gestational
hypertension probably beneﬁt from labour induction by
decreasing poor maternal outcome (RR 0.71, 95% CI 0.59,
0.86, preeclampsia and gestational hypertension data com-
bined) [379].
Preexisting hypertension. Among women with uncompli-
cated pre-existing hypertension, delivery at 380–396 weeks
appears to optimize the trade-off between the risk of ad-
verse fetal (stillbirth) or maternal complications (superim-
posed preeclampsia and abruption) that increase with
gestational age, and neonatal mortality and morbidity that
decreases in incidence with gestational age [381]. Trial
data are needed.
We were unable to identify data on the cost-effective-
ness of labour induction for women with a HDP before
340 weeks. For women with gestational hypertension or
preeclampsia near term (340–366 weeks), a policy of labour
induction is cost-effective based on neonatal and maternal
morbidity, based on controlled retrospective data; labour
induction cost CAD$299 more but was associated with bet-
ter quality of life [www.nice.org.uk/guidance] [382]. For
women with gestational hypertension or preeclampsia at
P370 weeks, labour induction is cost-saving (by
CAD$1,065) due to less antepartum resource use [383].
Mode of delivery
Recommendations
1. For women with any HDP, vaginal delivery should be
considered unless a Caesarean delivery is required for
the usual obstetric indications (II-2B; Low/Strong).
2. If vaginal delivery is planned and the cervix is unfavour-
able, then cervical ripening should be used to increase
the chance of a successful vaginal delivery (1-A; Moder-
ate/Strong).
3. At a gestational age remote from term, women with
HDP with evidence of fetal compromise may beneﬁt
from delivery by emergent Caesarean delivery (II-2B;
Low/Strong).
4. Antihypertensive treatment should be continued
throughout labour and delivery to maintain sBP at
<160 mmHg and dBP at <110mmHg (II-2B; Low/Strong).
5. The third stage of labour should be actively managed
with oxytocin 5 units IV or 10 units IM, particularly in
the presence of thrombocytopoenia or coagulopathy
(I-A; Moderate/Strong).
6. Ergometrine maleate should not be administered to
women with any HDP, particularly preeclampsia or ges-
tational hypertension; alternative oxytocics should be
considered (II-3D; Low/Strong).
Comments
All women with a HDP should be considered for labour
induction. Choosing the mode of delivery should consider
both the gestational age and fetal status. In severe early-
onset preeclampsia with clinical evidence of fetal compro-
mise, Caesarean may be preferable.
For labour induction, cervical ripening (even with an
unfavourable cervix), increases the chance of vaginal deliv-
ery [384,385]. With severe preeclampsia, this will take
more time and be less successful compared with normo-
tensive pregnancy [386,387]. Neither IUGR nor oligohy-
dramnios are contraindications to induction [388].
Rates of vaginal delivery after induction are 6.7–10% at
24–28 weeks (suggesting advisability of Caesarean with
viable fetuses), 47.5% at 28–32 weeks, 68.8% at 32–
34 weeks, and 30% with birthweights <1500 g [385,388–
391]. Vaginal delivery likelihood is reduced (but still
exceeds 50%) when there is increased umbilical artery
resistance [392,393]. The following predict Caesarean deliv-
ery: absent or reversed umbilical artery end-diastolic ﬂow,
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abnormal BPP, and abnormal sequential changes in
Doppler studies of the fetal circulation [394–397].
Preeclampsia is associated with thrombocytopoenia
and coagulopathy, and active management of the third
stage [398], avoiding ergometrine (ergonovine maleate),
should be performed to avoid postpartum haemorrhage
[399–404].
Anaesthesia, including ﬂuid administration and coagulation
concerns in neuraxial techniques
Recommendations – General principles
1. The anaesthesiologist should be informed when a
woman with preeclampsia is admitted to the delivery
suite (II-3B; Low/Strong).
2. Early insertion of an epidural catheter (in the absence of
contraindications) is recommended for control of
labour pain (I-A; Moderate-Strong/Strong).
3. In the absence of contraindications, all of the following
are acceptable methods of anaesthesia for women
undergoing Caesarean delivery: epidural, spinal, com-
bined spinal-epidural, and general anaesthesia (I-A;
Moderate-Strong/Strong).
4. A routine ﬁxed intravenous ﬂuid bolus should not be
administered prior to neuraxial anaesthesia (I-E; Low/
Strong).
Recommendations – Fluid administration
5. Intravenous and oral ﬂuid intake should be minimized
in women with preeclampsia, to avoid pulmonary
oedema (II-2B; Low/Strong).
6. Fluid should not be routinely administered to treat
oliguria (<15 mL/h for 6 consecutive hours) (III-D; Very
low/Weak).
7. For treatment of persistent oliguria, neither dopamine
nor furosemide is recommended (I-E; Moderate/Strong).
8. Phenylephrine or ephedrine may be used to prevent or
treat hypotension during neuraxial anaesthesia (I-A;
Moderate/Strong).
Recommendations – Monitoring
9. Arterial line insertion may be used for continuous arte-
rial BP monitoring when BP control is difﬁcult or there
is severe bleeding (II-3B; Very low/Strong).
10. Central venous pressure monitoring is not routinely
recommended, and if a central venous catheter is
inserted, it should be used to monitor trends and not
absolute values (II-2D; Very low-low/Strong).
11. Pulmonary artery catheterization is not recommended
unless there is a speciﬁc associated indication (III-D;
Very low/Strong), and then, only in an intensive care
unit setting (III-B; Very low/Strong).
Recommendations – Coagulation
12. Upon admission to delivery suite, women with pre-
eclampsia should have a platelet count done (II-1A;
Low/Strong).
13. Neuraxial analgesia and/or anaesthesia are appropriate
in women:
a. With preeclampsia, provided there are no associ-
ated coagulation concerns (see Table 8) (II-2E;
Very low/Weak);
Table 8
Eligibility for neuraxial anaesthesia.*
Treatment with ASA or heparin Normal platelet count Low platelet count & Normal INR
and aPTT
Abnormal INR or aPTT (regardless of
platelet count)£
None or Low dose ASA – if platelet count > 75x109/L Contraindicated
Unclear – if platelet count 50–
75x109/L
X – if platelet count < 50x109/L
UFH
<10,000 IU/d (SC) Unclear
0–4 h after last dose
>10,000 IU/d (SC) Unclear
4 h after last dose and a
normal aPTT
Therapeutic dose (iv) Unclear
4 h after last dose and a
normal aPTT
LMWH
Prophylactic dose Unclear
10–12 h after last dose
Therapeutic dose Unclear
24 h after last dose
Low dose ASA + prophylactic UFH
or LMWH||
Unclear
R
Unclear
ASA, aspirin; LMWH, low molecular weight heparin; SC, subcutaneous; UFH, unfractionated heparin).
* These recommendations are based on the absence of a rapidly falling platelet count or KNOWN platelet dysfunction (e.g., von Willebrand’s disease).
£ Other than a lupus anticoagulant.
|| Prophylactic doses of unfractionated heparin are deﬁned as 610,000 IU/d.R
Unless ASA is stopped 7 days or more before delivery.
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b. With a platelet count >75 109/L (II-2B; Moderate-
high/Strong);
c. Taking low-dose ASA in the presence of an ade-
quate platelet count (I-A; Very low/Weak);
d. Receiving unfractionated heparin (UFH) in a dose
of610,000 IU/d subcutaneously, 4 h after the last
dose and possibly immediately after the last dose
without any delay (III-B; Very low/Weak);
e. Receiving UFH in a dose >10,000 IU/d subcutane-
ously, if they have a normal aPTT 4 h after the
last dose (III-B; Very low/Weak);
f. Receiving intravenous heparin in a therapeutic
dose if they have a normal aPTT 4 h after the last
dose (III-B; Very low/Weak); or
g. Receiving low-molecular weight heparin (LMWH)
a minimum of 10–12 h after a prophylactic dose,
or 24 h after a therapeutic dose (III-B; Very low/
Weak).
General principles
Communication between caregivers is essential [2].
Early consultation (by telephone if necessary) with anaes-
thesia should occur, at the latest with delivery suite admis-
sion of a woman with preeclampsia. Anaesthesiologists
may co-manage hypertension, maternal end-organ dys-
function, and use of medications with anaesthesia/analge-
sia implications.
Early placement of an epidural catheter is advantageous
to: (i) attenuate labour pain-induced increases in cardiac
output and BP [405–407], and in the event that either (ii)
thrombocytopoenia develops or (iii) Caesarean delivery is
required. Neither epidural nor combined spinal-epidural,
analgesia harms the fetus [405,408,409] or increases Cae-
sarean delivery in severe preeclampsia [410,411].
If neuraxial analgesia and/or anaesthesia is contraindi-
cated, intravenous opioid analgesia is a reasonable alterna-
tive; but neonatal depression may result and require
naloxone [412].
For Caesarean delivery, spinal is preferred over epidural
anaesthesia (unless already placed) because of its more ra-
pid onset and smaller calibre needle [413]. If time permits,
spinal is preferred over general anaesthesia to avoid the
hypertensive response to intubation (attenuated by anti-
hypertensives or opioids); spinal is, however, associated
with lower cord pH and higher cord base deﬁcit of uncer-
tain clinical signiﬁcance [414–419]. Spinals do not alter
uteroplacental haemodynamics [420]. Difﬁcult (or failed)
intubation for general anaesthesia in women with HDPs
is more common [421,422].
Fluid administration. Routine preloading with a ﬁxed vol-
ume of crystalloid (i.e., 500–1000 mL) will not prevent BP
falls in normal women prior to Caesarean delivery [423];
no speciﬁc studies exist for HDPs. Preloading may increase
the risk of life-threatening pulmonary oedema [2]
Hypotension should be treated with vasopressors as an
infusion or small boluses [424].
Oliguria (<15 mL/h) is common in preeclampsia, partic-
ularly postpartum. In the absence of pre-existing renal
disease or a rising creatinine, oliguria should be tolerated
over hours, to avoid volume-dependent pulmonary
oedema [2,425,426]. Fluid balance should be closely
monitored, and furosemide limited to pulmonary oedema
treatment, as the beneﬁts of furosemide (and dopamine)
for oliguria are uncertain [427,428].
Monitoring. Early (<34 weeks) and late (P34 weeks) onset
preeclampsia may have different haemodynamics (i.e.,
low cardiac output (CO)/high systemic vascular resistance
(SVR) for the former and high CO/low SVR for the latter)
[429]. For resistant/labile hypertension, non-invasive or
minimally invasive haemodynamic assessment, particu-
larly transthoracic echocardiography, can be used to
guide therapy; results correlate well with invasive
monitoring [430].
Almost all women can be monitored effectively by vital
signs and oxygen saturation. Central venous pressure
(CVP) monitoring should be limited to haemodynamically
unstable women. CVP monitoring can be used for trends
(including response to therapy) rather than for diagnosis.
Pulmonary artery catheterization should be limited to the
ICU.
Neuraxial analgesia/anaesthesia and coagulation. Most
guidance for neuraxial anaesthesia in women with
preeclampsia and coagulation disorders comes from non-
obstetric literature and guidelines based mainly on expert
opinion.
All women with a HDP should have a platelet count,
noting the number and trend in the count. Tests of platelet
function are not indicated, as results do not correlate with
bleeding in the spinal space [431].
Neuraxial haematoma (in the epidural, spinal, or sub-
dural spaces) is rare (<1:150,000 epidurals, <1:220,000 spi-
nals) [432]. However, the potential to cause permanent
neurological dysfunction promotes concern in women
either with low platelet counts or taking medication affect-
ing coagulation [433]. These women should be assessed
soon after the block has worn off to exclude back pain or
new/progressive neurological complications [432].
s Thrombocytopoenia
Neuraxial haematomas have not been reported with plate-
let counts above 75  109/L, in the absence of platelet dys-
function or associated coagulopathy [434]. Practice varies
widely regarding an acceptable platelet count (range 50–
100  109/L) prior to neuraxial anaesthesia or catheter
removal [413,435]
s Aspirin
Women on low-dose aspirin (60–81 mg) are eligible for
neuraxial anaesthesia [436,437]. There is minimal evi-
dence about the safety of neuraxial anaesthesia for women
on higher doses of aspirin. Of 61 cases of neuraxial haema-
toma associated with non-obstetric neuraxial block, one
was associated with higher dose aspirin therapy [438],
while none of 674 patients who received preoperative
aspirin (median dose 350 mg) developed a spinal haema-
toma [439,440]. More recent cases of neuraxial haematom-
a associated with 81 mg of aspirin were associated with
concomitant heparin therapy [441].
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Coagulation tests are indicatedwith thrombocytopoenia,
maternal end-organ dysfunction of preeclampsia, or clinical
bleeding [80,87], with some anaesthesiologists testing rou-
tinely prior to neuraxial analgesia/anaesthesia [435,442].
s Heparin
Advice regarding anaesthetic management of the heparin-
ized patient differs, based largely on expert opinion [433].
Following a prophylactic dose of unfractionated heparin
(UFH) subcutaneously (maximum 10,000 IU/d), advice
varies from no delay to a delay of 4 h [433,443]; 4 h is
consistent with the known non-pregnancy UFH pharmaco-
kinetics despite an earlier peak effect in pregnancy [444].
While generally unnecessary, aPTT can be checked prior
to neuraxial analgesia/anaesthesia [433,445].
With therapeutic subcutaneous UFH, an aPTT P4 h
after the last dose should be conﬁrmed to be normal prior
to initiating neuraxial analgesia/anaesthesia or removing a
neuraxial catheter.
When to initiate prophylactic or therapeutic UFH after
neuraxial block is at least one hour following either block
placement or catheter removal [433,443,446].
Women on LMWH are ineligible for neuraxial anaesthe-
sia until at least 10–12 h (prophylactic dose) or 24 h
(therapeutic dose) after their last dose, based on non-
pregnancy reports of neuraxial haematomas [443]. Some
anaesthesiologists prefer to wait 24 h after any dose.
Therefore, switching from prophylactic LMWH to UFH is
common in late pregnancy [447].
If there were blood in the needle or epidural catheter
when siting a neuraxial block, initiating LMWH should be
delayed for 24 h [443], during which period early mobiliza-
tion and non-pharmacological methods can be used in
women at higher thromboembolic risk.
Indwelling neuraxial catheters can be maintained with
prophylactic doses of UFH (610,000 IU/day) and single-
daily prophylactic LMWH, without use of other haemosta-
sis-altering agents.
s Aspirin and heparin
Based on non-obstetric data, women receiving aspirin and
either prophylactic LMWH or UFH are at higher risk of
neuraxial haematomas. Neuraxial anaesthesia should be
avoided in patients on aspirin (>75 mg daily) and LMWH
[443], aspirin could be discontinued 2–3 days prior to
neuraxial anaesthesia if preoperative heparin thrombopro-
phylaxis is used [445,446].
Aspects of care speciﬁc to women with pre-existing
hypertension
Recommendations
1. Pre-conceptual counselling for women with pre-exist-
ing hypertension is recommended (III-C; Very low/
Weak).
2. The following antihypertensive drugs are acceptable for
use in the ﬁrst trimester of pregnancy: methyldopa,
labetalol, and nifedipine (all II-2B; all Low/Weak).
3. ACE inhibitors and ARBs should be discontinued when
planning pregnancy or as soon as pregnancy is diag-
nosed (II-2D; Low/Weak).
4. Atenolol should be discontinued when pregnancy is
diagnosed (I-D; Low/Weak).
5. Planned changes in antihypertensive agent(s) for care in
pregnancy should be made while the woman is plan-
ning pregnancy if the woman has uncomplicated pre-
existing hypertension, or, if in the presence of comorbid
conditions, she is likely to conceive easily (within
12 months) (III-L; Very low/Weak).
Comments
The major issues to address are the teratogenicity of
antihypertensives, continuing antihypertensives during
pregnancy, and continuing pre-pregnancy cardiovascular
risk reduction therapy (e.g., aspirin, statins).
Pre-conceptual counselling is ideal, but as 50% of preg-
nancies are unplanned, inadvertent antihypertensive expo-
sures will occur. Contraception efﬁcacy and the potential
for teratogenicity must be considered when prescribing
antihypertensives to reproductive age women, all of whom
should take P0.4 mg/day of folate prior to pregnancy.
As BP usually falls in pregnancy (nadir 20 weeks), be-
fore rising towards pre-pregnancy levels by term, women
with pre-existing hypertension may not need to continue
antihypertensives from early pregnancy. Antihypertensive
discontinuation does not alter preeclampsia risk [448]
(see Antihypertensive therapy.)
Any potential teratogenicitymust be assessed relative to
the baseline risk of major malformations: 1–5% of pregnan-
cies. Most antihypertensives have not been found to be ter-
atogenic, but the quality of the information is only fair for
most. The 2010 UK NICE guidelines describe thiazides as
teratogenic (unsupported statement). ACE inhibitors may
increase the risk of major (particularly cardiovascular or
central nervous system) malformations [449]. [Teratoge-
nicity information is readily available from the DART data-
base [450] and Motherisk, www.motherisk.org.] The
adverse effects of atenolol on fetal growth have been partic-
ularly associated with use from early pregnancy [354–358].
Whether or when to replace ACE inhibitors, angioten-
sin-receptor blockers (ARBs), atenolol, or less commonly
used antihypertensives pre-pregnancy or when pregnancy
is diagnosed, and if so, with what is uncertain, but the fol-
lowing should be considered:
Is there an alternative agent available?. If ACE inhibitors and
ARBs are being given for renoprotection, no equivalent
agent is available for use in pregnancy; however, much of
ACE/ARB-related renoprotection is provided lowering BP,
achievable by alternatives [7].
How long will conception take?. Normally, conception may
take up to 12 months, but women over 30 years have a
higher incidence of subfertility. If an ACE inhibitor is dis-
continued pre-pregnancy in a woman with renal disease,
yet conception does not occur after 12 months and pro-
teinuria is rising despite excellent BP control (i.e., <140/
90 mmHg), it may be prudent to reinstate ACE inhibition,
perform monthly pregnancy tests, and proceed with
investigations of subfertility. A multidisciplinary approach
towards comorbidities and/or cardiovascular risk factors is
recommended.
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Although existing data are reassuring about use of stat-
ins in pregnancy, they should be discontinued pre-preg-
nancy or as soon as pregnancy is diagnosed until further
data are available. Information about safety with treatment
at 240–336 weeks will come from the StAmP Trial (ISRCTN
23410175).
For information on management of renal disease in
pregnancy, see the update by Davison [451].
Aspects of care for women with preeclampsia
Magnesium sulfate (MgSO4) for eclampsia (Prophylaxis or
Treatment)
Recommendations
1. MgSO4 is recommended for ﬁrst-line treatment of
eclampsia (I-A; High/Strong).
2. MgSO4 is recommended as prophylaxis against eclampsia
in women with severe preeclampsia (I-A; High/Strong).
3. MgSO4 may be considered as prophylaxis against
eclampsia in women with non-severe preeclampsia
with severe hypertension, headaches/visual symptoms,
right upper quadrant/epigastric pain, platelet count
<100,000  109/L, progressive renal insufﬁciency, and/
or elevated liver enzymes, based on cost considerations
(I-C; Moderate/Strong).
4. MgSO4 should be used in standard dosing, usually 4 g IV
loading dose followed by 1 g/h (I-A; Moderate/Strong).
5. Routine monitoring of serum Mg levels is not recom-
mended (I-E; Low/Strong).
6. Phenytoin and benzodiazepines should not be used for
eclampsia prophylaxis or treatment, unless there is a
contraindication to MgSO4 or it is ineffective (I-E;
High/Strong).
7. In women with pre-existing or gestational hyperten-
sion, MgSO4 should be considered for fetal neuroprotec-
tion in the setting of ‘imminent preterm birth’ (within
the next 24 h) at 6316 weeks (1-A; Moderate/Strong).
8. Delivery should not be delayed in order to administer
antenatal MgSO4 for fetal neuroprotection if there are
maternal and/or fetal indications of emergency delivery
(III-E; Very low/Strong).
Comments
For eclampsia, MgSO4 more than halves recurrent sei-
zure rates compared with phenytoin [452], diazepam
[453], or a lytic cocktail [454]. Also, MgSO4 (vs. diazepam)
reduces maternal death; benzodiazepines should not be
used for seizure termination. Loading is with MgSO4 4 g
IV (or 5 g in South Africa) over 5 min, followed by infusion
of 1 g/h. Treatment of any recurrent seizures is with
another 2–4 g IV over 5 min. Serum Mg2+ levels are unnec-
essary, with women followed clinically for adverse
Mg2+-related effects.
In women with preeclampsia, MgSO4 (vs. placebo or no
therapy) more than halves eclampsia occurrence (RR 0.41;
95% CI 0.29–0.58) [455,456]. Loading is with MgSO4 4 g IV
over 10–15 min, followed by infusion of 1 g/h. The NNT
(95% CI) to prevent one seizure is 50 (34–100) with severe
preeclampsia and 100 (100–500) with non-severe pre-
eclampsia. MgSO4 decreases abruption risk (RR 0.64; 95%
CI 0.50–0.83; NNT 100 [50–1000]) but increases Caesarean
delivery (RR 1.05; 95% CI 1.01–1.10) and side effects (RR
5.26; 95% CI 4.59– 6.03). MgSO4 (vs. phenytoin) reduces
eclampsia (RR 0.08; 95% CI 0.01–0.60) but increases Cae-
sarean delivery (RR 1.21; 95% CI 1.05–1.41) [455]. MgSO4
(vs. nimodipine) reduces eclampsia, but there were more
respiratory problems (RR 3.61; 95% CI 1.01–12.91) and
the need for additional antihypertensives (RR 1.19; 95%
CI 1.08–1.31) [455].
In preeclampsia, although the risk of eclampsia is
lower with MgSO4 (vs. placebo, no therapy, or other anti-
convulsants), it is controversial whether women with
non-severe preeclampsia should receive MgSO4, due to
Caesarean delivery and maternal adverse effect risks, as
well as cost (i.e., US$23000 to prevent one seizure if
administered to all women with preeclampsia) [457].
There is no international consensus on what deﬁnes se-
vere pre-eclampsia. This document deﬁnes it as pre-
eclampsia requiring delivery, due to serious maternal
end-organ involvement and/or fetal compromise (see
Classiﬁcation). For eclampsia prevention in the setting of
non-severe pre-eclampsia, we have added to the indica-
tion for MgSO4 (in recommendation 3 above), the follow-
ing symptoms/signs as these are included in the
deﬁnition of severe pre-eclampsia by other organizations:
severe hypertension, headaches/visual symptoms, right
upper quadrant/epigastric pain, platelet count
<100,000  109/L, progressive renal insufﬁciency, and/or
elevated liver enzymes. However, it should be noted that
moving from universal prophylaxis to selection of only
those women with more severe disease may increase
(marginally) eclampsia and associated general anaesthe-
sia and adverse neonatal outcomes [458].
The role of modiﬁed MgSO4 protocols is uncertain (i.e.,
eclampsia treatment with loading dose-only or low-dose
regimens, and eclampsia prevention with abbreviated
postpartum courses vs. 24 h of treatment) [459–463].
MgSO4 is recommended for fetal neuroprotection in the
setting of imminent preterm birth (within the next 24 h)
at 6316 weeks, and could be considered at up to 336 weeks
[464].
For MgSO4 treatment of eclampsia, we were unable to
identify a cost-effectiveness analysis. For women with
pre-eclampsia, MgSO4 prevents eclampsia but costs more
(vs. no treatment) [457]. In high income countries, the
NNT to prevent one case of eclampsia is 43 [68], with an
incremental cost of US$21,202; this would be $12,942 if
treatment were restricted to severe preeclampsia. Conven-
tionally, $50,000 per case prevented is the threshold for
‘willingness to pay’. MgSO4 for fetal neuroprotection (vs.
no treatment) is highly cost-effective [465].
Plasma volume expansion for preeclampsia
Recommendation
1. Plasma volume expansion is not recommended for
women with preeclampsia (I-E; Moderate/Strong).
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Comments
Women with preeclampsia are intravascularly volume
contracted with high sympathetic tone. Colloid solutions
do not improve maternal, perinatal or 12 month neurode-
velopmental outcomes, but may increase Caesarean deliv-
eries, decrease pregnancy prolongation, and increase
pulmonary oedema [466,467].
Therapies for HELLP syndrome
Recommendations
1. Every obstetrical centre should be aware of the local
delay between ordering and receiving platelets units
(IIIB; Very low/Strong).
2. For a platelet count <20  109/L with HELLP, platelet
transfusion is recommended, regardless of mode of
delivery (IIIB; Low/Strong).
3. For a platelet count 20–49  109/L with HELLP, platelet
transfusion is recommended prior to Caesarean delivery
(IIIB; Low/Strong).
4. For a platelet count 20–49  109/L with HELLP, platelet
transfusion should be considered prior to vaginal deliv-
ery if there is excessive active bleeding, known platelet
dysfunction, a rapidly falling platelet count, or coagu-
lopathy (II-2D; Low/Weak).
5. For a platelet count ofP50  109/L with HELLP, platelet
transfusion and/or packed red blood cells should be
considered prior to either Caesarean or vaginal delivery
only if there is excessive active bleeding, known platelet
dysfunction, a rapidly falling platelet count, or coagu-
lopathy (IIIB; Low/Weak).
6. We do not recommend corticosteroids for treatment of
HELLP until they have been proven to decrease mater-
nal morbidity (II-3L; Low-Moderate/Weak).
7. We recommend against plasma exchange or plasma-
pheresis for HELLP, particularly within the ﬁrst four
days postpartum (II-3E; Low/Strong).
Comments
HELLP syndrome must be differentiated from other
‘imitators’ (see ‘Investigations to diagnosis the HDP, When
preeclampsia is suspected’).
Table 9 presents platelet transfusion recommendations
for HELLP [468,469], as platelet counts <10–20  109/L
increase the risk of profound haemorrhage even with
non-operative delivery [470]. The platelet count may de-
crease rapidly in HELLP, mandating frequent serial mea-
surement of platelet count (within hours), depending on
the clinical condition. Clinicians should be aware of the po-
tential for delays when ordering platelets or other blood
products. Anti-D(Rho) sensitization can be prevented by
anti-D prophylaxis (300 lg dose anti-D immune globulin)
in Rh D negative women [470].
HELLP does not improve immediately after delivery [471],
as most women’s platelet counts fall and liver enzymes rise
until day two postpartum, usually improving by day four
such that by day six (or within 3 days of the platelet nadir),
the platelet count should be P100 109/L.
For HELLP, corticosteroids (dexamethasone more than
betamethasone), especially if initiated before delivery,
signiﬁcantly improve platelet counts and other haemato-
logical and biochemical indices (ALT, AST, and LDH), but
without a signiﬁcant impact on major maternal or perina-
tal outcomes (death or severe morbidity) [472]. Regional
anaesthesia may be achieved more often with corticoste-
roids [473]. By incorporating dexamethasone into a local
HELLP protocol (along with MgSO4 and antihypertensives),
one centre noted less severe maternal morbidity and dis-
ease progression [474].
Women with progressive HELLP, particularly postpar-
tum, may improve with plasma therapies effective for
thrombotic thrombocytopenic purpura (TTP) [475]. No
RCTs were identiﬁed.
Also, see ‘Timing of delivery’.
Postpartum treatment
Care in the 6 weeks post partum
Recommendations
1. BP should be measured during the time of peak post-
partum BP, at days three to six after delivery (III-B;
Low/Strong).
Table 9
Recommendations about TRANSFUSION of platelets related to mode of delivery in HELLP.
Platelet count Mode of delivery
Cesarean delivery Vaginal delivery
<20  109/L Recommend Recommend
20–49  109/L Recommend Consider in presence of:
 Excessive active bleeding
 Known platelet dysfunction
 Platelet count falling rapidly
 Coagulopathy
P50  109/L Consider in presence of: Consider in presence of:
 Excessive active bleeding
 Known platelet dysfunction
 Platelet count falling rapidly
 Coagulopathy
 Excessive active bleeding
 Known platelet dysfunction
 Platelet count falling rapidly
 Coagulopathy
Regardless of the platelet count No platelets should be transfused if there is a strong suspicion of HIT or TTP-HUS
HIT, heparin-induced thrombocytopoenia; TTP-HUS, thrombotic thrombocytopoenic purpura – haemolytic uraemic syndrome.
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2. Women with postpartum hypertension should be
evaluated for pre-eclampsia (either arising de novo
or worsening from the antenatal period) (II-2 B;
Low/Weak).
3. Consideration should be given to continuing antihy-
pertensive therapy postpartum, particularly in
women with antenatal preeclampsia and those
who delivered preterm (II-2I; Low/Weak).
4. Severe postpartum hypertension must be treated with
antihypertensive therapy, to keep sBP <160mmHg
and diastolic BP <110mmHg (IA; Moderate/Strong).
5. In women without co-morbidities, antihypertensive
therapy should be considered to treat non-severe
postpartum hypertension to keep BP <140/90 mmHg
(III-I; Very low/Weak).
6. Women with co-morbidities other than pre-gesta-
tional diabetes mellitus should be treated to keep
BP <140/90 mmHg (III-C; Very low/Weak).
7. Women with pre-gestational diabetes mellitus
should be treated to keep BP <130/80 mmHg (III-C;
Very low/Weak).
8. Antihypertensive agents generally acceptable for use
in breastfeeding include the following: nifedipine
XL, labetalol, methyldopa, captopril, and enalapril
(III-B; Moderate/Weak).
9. There should be conﬁrmation that end-organ dys-
function of preeclampsia has resolved (III-C; Very
low/Strong).
10. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
should not be given postpartum if hypertension is
difﬁcult to control, there is evidence of kidney injury
(oliguria and/or an elevated creatinine) (P90 lM) or
platelets are <50–109/L (III-C; Low/Weak).
11. Postpartum thromboprophylaxis should be consid-
ered in women with preeclampsia, particularly in
the presence of other risk factors (II-2B; Low/Weak).
Comments
Postpartum hypertension. Hypertension may antedate
delivery in up to 50% of women with postpartum hyperten-
sion. Women with pre-existing hypertension not requiring
antihypertensives antenatally may require antihyperten-
sives early in the puerperium [476]. Those at greatest risk
of postpartum hypertension are those who delivered
preterm, and, for multiparous women, those with higher
urate levels [477,478]. Postpartum deterioration of mater-
nal end-organ function occurs in up to 25%, usually in the
early puerperium, especially with severe disease [479].
De novo postpartum hypertension is most common on
days three to six [480]. It may be isolated or associated
with preeclampsia-related end-organ dysfunction. Two
thirds of women with postpartum preeclampsia had no
antenatal HDP and their postpartum preeclampsia/
eclampsia usually develops within days, but occasionally
up to three weeks, after delivery [481].
Management. There are no reliable data to guide whether
or not antenatal antihypertensives should be continued
postpartum, and which antihypertensive to choose.
All severe hypertension should be treated, be it antena-
tal or postpartum. Based on non-pregnancy data, BP should
be treated to <140/90 mmHg in women with a co-morbid
condition, and further to <130/80 mmHg in women with
pre-gestational diabetes mellitus [7].
There is no clear best choice of agent [482]. Antihyper-
tensives used most commonly in pregnancy, as well as
captoprial and enalapril are ‘‘usually acceptable’’ for
breastfeeding [483,484], but caution may be exercised in
preterm and low birth weight infants due to immature
drug clearance and/or increased susceptibility to drug ef-
fects. Generally, antihypertensives are needed longer in
women with preeclampsia (2 weeks) vs. gestational
hypertension (1 week) [18].
Postpartum analgesia. Non-steroidal anti-inﬂammatory
drugs (NSAIDs), often self-administered analgesics, may
exacerbate hypertension or cause acute kidney injury,
and may best be avoided with resistant hypertension, high
serum creatinine, or low platelet counts [485].
Postpartum thromboprophylaxis. Thromboprophylaxis use
should be based on number of thromboembolic risk markers,
especially preeclampsia associated with adverse perinatal
outcome, advanced maternal age, obesity, prolonged antena-
tal bed rest, postpartum haemorrhage, and emergency
Caesarean delivery [297,486,487]. The duration of thrombo-
prophylaxis may vary from until full mobilization to
4–6 weeks postpartum (also, see ‘Anaesthesia’).
Care beyond 6 weeks post partum
Recommendations
1. Women with a history of severe preeclampsia
(particularly those who presented or delivered
before 34 weeks’ gestation) should be screened for
pre-existing hypertension and underlying renal disease
(II-2B; Low/Weak).
2. Referral for internal medicine or nephrology consulta-
tion (by telephone if necessary) should be considered
for women with: (i) postpartum hypertension that is
difﬁcult to control, or (ii) women who had preeclampsia
and have at 3–6 months postpartum either ongoing
proteinuria, decreased eGFR (<60 ml/min), or another
indication of renal disease (such as abnormal urinary
sediment) (III-A; Low/Weak).
3. Women who are overweight should be encouraged to
attain a healthy body mass index to decrease risk in
future pregnancy (II-2A; Moderate/Strong) and for
long-term health (I-A; Low-moderate/Strong).
4. Women with pre-existing hypertension or persistent
postpartum hypertension should undergo the following
investigations (if not done previously) at least 6 weeks
postpartum: urinalysis; serum sodium, potassium and
creatinine; fasting glucose; fasting lipid proﬁle; and stan-
dard 12-lead electrocardiography (III-I; Low/Weak).
5. Women who are normotensive but who have had a
HDP, may beneﬁt from assessment of traditional cardio-
vascular risk markers (II-2B; Low-moderate/Weak).
6. All women who have had a HDP should pursue a
healthy diet and lifestyle (I-B; Low/Weak).
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Comments
Gestational hypertension usually resolves by 6 weeks
postpartum, while the hypertension of severe preeclamp-
sia may take 3–6 months [488]. Routine measurement of
microalbuminuria after preeclampsia resolution is not rec-
ommended without a speciﬁc renal indication. Any abnor-
malities should prompt further investigation and
appropriate specialist referral.
Future pregnancy. Screening for other underlying causes of
preeclampsia (e.g., renal disease) may better inform man-
agement of the woman’s health between (or after) preg-
nancies, or in subsequent pregnancies. Thrombophilia
confers, at most, a weakly increased risk of preeclampsia
(and other placentally mediated pregnancy complications),
and thrombophilia screening following preeclampsia is not
recommended [489]. One exception may be preeclampsia
with delivery at <34 weeks following which testing for
antiphospholipid antibodies could be undertaken to diag-
nose the antiphospholipid syndrome [490].
Long-term maternal health. Any weight gain between preg-
nancies predicts preeclampsia and other pregnancy com-
plications [491]. Observational data suggest that in
women who are morbidly obese, bariatric surgery lowers
rates of subsequent HDP [492].
Women with pre-existing hypertension should receive
recommended cardiovascular risk factor screening and
treatment [493].
As pregnancy is a biological ‘stress test’ of sorts, women
with a prior HDP (particularly associated with preterm
delivery or adverse perinatal outcome) should be informed
of their increased future health risks, including; hyperten-
sion; cardiovascular and cerebrovascular morbidity and
mortality; subsequent renal disease; thromboembolism;
hypothyroidism; and type 2 diabetes mellitus [494–503].
It is unclear whether the microalbuminuria associated
with previous preeclampsia represents underlying renal
disease or is an independent cardiovascular risk marker
[504]. That early testing (and intervention) for cardiovas-
cular and renal risk factors will improve cardiovascular
outcomes is unproven.
Barriers to compliance with a healthy diet and lifestyle
include poor postpartum physical and psychological recov-
ery, and lack of postpartummedical and psychological sup-
port from healthcare providers [505].
Long term offspring health. Be aware of a growing literature
describing adverse effects of preeclampsia on offspring car-
diovascular [506] and reproductive health [507].
Effects of maternal hypertension and its’ therapies on child
neurobehavioral development
Recommendations
1. Clinicians should be aware that gestational hyperten-
sion and preeclampsia may each be associated with
an increase in adverse paediatric neurodevelopmental
effects, such as inattention and externalizing behav-
iours (e.g., aggressiveness) (II2-B; Very low/Weak).
2. Clinicians should be reassured that there is no compel-
ling evidence that antihypertensive medications (spe-
ciﬁcally labetalol, nifedipine, or methyldopa) are
themselves associated with clear adverse neurodevel-
opmental effects (I-B; Low/Weak).
Comments
Superimposed preeclampsia (vs. pre-existing hyperten-
sion alone) has no adverse effect on (or slightly better)
intellectual development (no information given on antihy-
pertensives) [508].
Gestational hypertension and preeclampsia may predict
generally modest long term effects on child development.
Children ofwomenwith preeclampsia had reduced internal-
izingmorbidity (e.g., anxiety) at ages 5 and 8 years, but chil-
dren of women with gestational hypertension were more
likely to have poorer behaviour from 8 years onwards, with
the largest difference seen at 14 years (no information given
on antihypertensives) [509]. Both types of HDPwere associ-
ated with a small reduction in verbal ability of uncertain
clinical signiﬁcance [510]. Little information was provided
on antihypertensives which were considered as a covariate.
Babies of antihypertensive (mainly methyldopa)-treated
mothers (vs. normtensive controls) have excess delayed
ﬁne-motor function at 6 months of age, while those of pla-
cebo-treated hypertensive mothers more frequently had
‘questionable’ neurological assessment and delayed gross-
motor function at 12 months [511]. However other small
RCTs of methyldopa [512], atenolol [347], and nifedipine
[513] did not observe negative impacts on child develop-
ment. Methyldopa (but not labetalol) may be associated
with lower IQ; the duration of treatment being an indepen-
dent negative predictor of children’s Performance IQ [514].
Chapter 4: Patient perspective
Recommendations
1. Health care providers should be alert to symptoms of post-
traumatic stress following a HDP; and refer women for
appropriate evaluation and treatment (II-2B; Low/Weak).
2. Health care providers should inform their patients,
antepartum and postpartum, about pre-eclampsia, its
signs and symptoms, and the importance of timely
reporting of symptoms to health care providers (II-2;
Very low/Weak).
3. Information should be re-emphasized at subsequent
visits (III-C; Very low/Weak).
Comments
We support incorporating the patient perspective into
care. Engaged patient advocacy organizations are the
Preeclampsia Foundation www.preeclampsia.org/), Action
on Pre-eclampsia (APEC) www.apec.org.uk/), Australian
Action on Pre-eclampsia (AAPEC) www.aapec.org.au),
New Zealand Action on Pre-eclampsia (NZ APEC) (www.
nzapec.com/), and Association de Prevention et d’Actions
contre la pre-eclampsie (APAPE) (www.eclampsie.moonfruit.fr/)
[515]. The Preeclampsia Foundation advocates for: better
patient (and health care provider) education about the ante-
natal, early postnatal and long-term maternal implications
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of preeclampsia; an emphasis on early maternal signs and
symptoms of preeclampsia; better doctor–patient commu-
nication about preeclampsia; and evidence-based guidelines for
pre-eclampsia screening, detection; and management [515].
Post traumatic stress
There is growing evidence that women may experience
post-traumatic stress disorder up to seven years postpar-
tum [516–524], the prevalence of symptoms being highly
variable, ranging from the minority to the majority of wo-
men, and higher after: maternal hospitalization >7 days,
HDP onset/delivery preterm, NICU admission, adverse neo-
natal outcomes, and uncertainty about the child’s long-
term health [519]. Symptoms are not speciﬁc to the HDP,
and follow preterm delivery for other indications [520].
Although post-traumatic stress symptoms do not have an
impact on infant cognitive or psychomotor development
at one year of age, maternal symptoms are amenable to
clinical psychological therapy, and earlier referral may
abbreviate treatment [523].
Women and their maternity care providers seem to
view experiences of preeclampsia differently. For health-
care professionals, preeclampsia represented the care that
must be delivered, primarily responding to the biology of
preeclampsia. For women, generally lacking knowledge
and understanding about pre-eclampsia, preeclampsia rep-
resented fear and risk [525].
Patient education and engagement
In a survey of women who had experienced preeclamp-
sia, eclampsia and/or HELLP, preeclampsia was viewed as
very important to all and traumatic to many respondents,
women, their partners, close relatives, or friends. The pro-
vision of information and support was valued prior to, and
at the time of, diagnosis as well as being revisited during
ongoing care [526].
Women are not knowledgeable about the HDP, even with
pre-existing hypertension, and are not satisﬁed with the
medical information they receive, suggesting that clinicians
should both place more value on informing women about
their disease and its potential course, and check that women
have understood the information [527,528]. Although limited
health literacy may complicate risk communication, tools
have been developed for such purposes [527,528].
Women enjoy participating in aspects of their care, be it
receiving information as study participants [529], or par-
ticipating in management of their BP [530]. They do not
object to being randomized [380].
Women have expressed a preference for home or day
care [531] and self (rather than 24-h ambulatory) BP mon-
itoring [532].
Chapter 5: Knowledge Translation tools and
implementation of the guideline
Knowledge translation tools
Table 10 lists tools to support the application of this
guideline. Some websites provide general information
about BP measurement for non-pregnant patients, but
the recommendations are similar enough to those in
pregnancy to be useful. Patients, their partners and care
providers should be well educated about the HDP and
relevant sites are listed.
Implementation of the guideline
Implementation of any evidence depends on individual
knowledgeandbeliefs, aswell as institutional culture. Strong
recommendations should be incorporated into clinical prac-
tice. In well-resourced settings, almost all preeclampsia-re-
lated maternal deaths involve substandard care [534].
Some recommendations may require additional effort
to implement, as highlighted below.
 One of the new recommendations regarding blood pres-
sure devices is: ‘The accuracy of all BP measurement
devices used in hospitals or ofﬁces should be checked
regularly against a calibrated device.’’ This might be
something that not all Canadian hospitals and ofﬁces
do on a regular basis.
 Physicians should consider the category ‘other HDP’
(which constitutes white coat and masked hyperten-
sion) as part of the classiﬁcation of hypertensive
women and consider using some form of out of ofﬁce
BP measurement to evaluate women with non-severe
pre-existing or gestational hypertension.
 Health care providers should inform pregnant women
about the symptoms and signs of the HDPs and refer
them to appropriate knowledge translation tools.
 We recommend the use of corticosteroids for women at
6346 weeks who are at high risk of delivery within the
next seven days. This gestational age cut-off represents a
fundamental change in practice that will require discussion.
 Physicians should be familiar with blood bank policies
of their own hospital.
 Physicians should be aware of postpartum signs of
maternal post traumatic stress disorder and maternal
and perinatal long term effects of HDPs, especially as
this is a ‘vulnerable’ time in maternal care when the
maternity care provider is often handing back care to
the primary care physician.
Chapter 6: Future directions
There are many areas in which important research is
pending, such as the CHIPS trial of antihypertensive ther-
apy and its impact on perinatal and maternal outcomes
and the TIPPS trial of heparin thromboprophylaxis to pre-
vent recurrent placental complications (including pre-
eclampsia). There are also many important research
questions for which answers are currently unavailable. Cli-
nicians are encouraged to participate in clinical research. If
the paediatric oncology research network can enrol more
than 60% of their patients in RCTs, then the maternity care
community should be able to improve on the <10% recruit-
ment rate of women by incorporating clinical research into
medical practice [535].
Ethics statement
These recommendations have been reviewed and ap-
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Table 10
Knowledge translation tools for HDP.
Tool Resource Comment
Patient information
BP measurement by patients
Canadian Hypertension Education
Program (CHEP)
http://www.hypertension.ca/measuring-
blood-pressure (English)
This website gives patients basic information about BP
measurement and gives instructions on self-measurement
http://www.hypertension.ca/fr/mesures-dp1
(French)
National Heart Foundation of
Australia
http://www.heartfoundation.org.au/
SiteCollectionDocuments/Self-Management-
BP.pdf
This website gives information about the self measurement
of BP by patients and advice about buying a machine
Heart and Stroke Foundation https://ehealth.heartandstroke.ca/heartstroke/
bpap.net/vid_measure_bp.html
This link refers to a movie that gives instructions for self
measurement of BP
Société canadienne d’hypertension http://hypertension.ca/measuring-blood-
pressure
Detailed information in English and French (with a poster in
English) although the images are of older patients
http://hypertension.ca/fr/mesures-dp1
Canadian Hypertension Education
Program (CHEP)
https://www.youtube.com/
watch?v=eqajdX5XU9Y&feasture=plcp
Detailed video on home BP measurement (outside
pregnancy)
Brochure RCOG.org.uk This also includes your risk of recurrence
BP measurement and pre-existing hypertension
Heart and Stroke Foundation www.heartandstroke.ca This website gives information about hypertension outside of
pregnancy, blood pressure monitoring and medication
Impact of pre-existing hypertension on pregnancy
American Heart Association
document: Chronic
Hypertension in Pregnancy
[533] This document explains in an understandable way how
chronic hypertension and pregnancy inﬂuence each other
and what the symptoms of preeclampsia that women should
be aware of
Preeclampsia awareness
Preeclampsia Education Tool Preeclampsia Foundation This tool explains the risks and symptoms of preeclampsia
and how to act on them. This tool has shown to be effective in
improving patient knowledge in a RCT (120 women) [528]
http://www.preeclampsia.org/market-place
Educational magnets and symptom
Pads
Preeclampsia Foundation Quick checklists of signs and symptoms of preeclampsia
http://www.preeclampsia.org/market-place
Patient education once preeclampsia develops
Brochures: Preeclampsia Foundation These are available in English and Spanish
 HELLP syndrome
 Preeclampsia FAQ
 Preeclampsia and heart
diseases
http://www.preeclampsia.org/market-place
Hôpital Maisonneuve-Rosemont,
Centre afﬁlié à l’Université de
Montréal: Brochure on pre-
eclampsia.
http://biblio.hmr.qc.ca/Publications_pdf/H/
hypertension_sfe080.pdf
French brochure for patients about preeclampsia
Patient education after preeclampsia
Educational pamphlet Preeclampsia Foundation Educational brochure about cardiovascular risks associated
with preeclampsiaAPEC
Health care provider information
BP measurement
WHO document: detecting
preeclampsia, a practical guide,
2005
http://www.who.int/reproductivehealth/
publications/maternal_perinatal_health/
MSM_92_3_/en/index.html
This document contains instructions how to measure blood
pressure and proteinuria in pregnant women, and how to
diagnose hypertensive disorders in pregnancy. This tool is for
health care providers
Approved BP measurement devices
Canadian Hypertension Education
Program (CHEP)
http://www.hypertension.ca/devices-
endorsed-by-hypertension-canada-dp1
This website gives an oversight of recommended blood
pressure devices
Educational Trust http://www.dableducational.org/
sphygmomanometers/devices_1_clinical.html
This website gives an oversight of recommended blood
pressure devices, outside of and during pregnancy
Clinical practice guidelines from other countries
NICE guidelines (UK, 2010) http://www.nice.org.uk/nicemedia/live/13098/
50475/50475.pdf
Graded recommendations
Australasian guidelines (Australia
and New Zealand, 2008)
http://www.somanz.org/pdfs/
somanz_guidelines_2008.pdf
Very practical but evidence not graded
American guidelines [98]
WHO guidelines http://whqlibdoc.who.int/publications/2011/
9789241548335_eng.pdf
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Appendix A
Appendix Table A1
Key to evidence statements and grading of recommendations, using the ranking of the Canadian Task Force on Preventive Health Care.
Quality of evidence assessment* Classiﬁcation of recommendations
I: Evidence obtained from at least one properly randomized controlled trial A. There is good evidence to recommend the clinical preventive action
II-1: Evidence from well-designed controlled trials without
randomization
B. There is fair evidence to recommend the clinical preventive action
II-2: Evidence from well-designed cohort (prospective or retrospective)
or case-control studies, preferably from more than one centre or
research group
C. The existing evidence is conﬂicting and does not allow to make a
recommendation for or against use of the clinical preventive action;
however, other factors may inﬂuence decision-making
II-3: Evidence obtained from comparisons between times or places with
or without the intervention. Dramatic results in uncontrolled
experiments (such as the results of treatment with penicillin in the
1940s) could also be included in the category
D. There is fair evidence to recommend against the clinical preventive
action
E. There is good evidence to recommend against the clinical preventive
action
III: Opinions of respected authorities, based on clinical experience,
descriptive studies, or reports of expert committees
L. There is insufﬁcient evidence (in quantity or quality) to make a
recommendation; however, other factors may inﬂuence decision-making
* The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force on
Preventive Health Care.
 Recommendations included in these guidelines have been adapted from the Classiﬁcation of recommendations criteria described in The Canadian Task
Force on Preventive Health Care [5].
Appendix Table A2
GRADE deﬁnitions for quality of evidence and strength of recommendations [6].
Quality of the evidence
High We are very conﬁdent that the true effect lies close to that of the estimate of the effect
Moderate We are moderately conﬁdent in the effect estimate. The true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different
Low Our conﬁdence in the effect estimate is limited. The true effect may be substantially different from the
estimate of the effect
Very low We have very little conﬁdence in the effect estimate. The true effect is likely to be substantially different from
the estimate of the effect
Strength of recommendations
Strong
For patients/public We believe most people in this situation would want the recommended course of action and only a small
number would not
For clinicians The recommendation would apply to most individuals. Formal decision aids are not likely to be needed to help
individuals make decisions consistent with their values and preferences
For policy makers and developers of
quality measures
The recommendation can be adopted as policy in most situations. Adherence to this recommendation
according to the guideline could be used as a quality criterion or performance indicator
Weak
For patients/public We believe that most people in this situation would want the recommended course of action, but many would
not. Different choices are acceptable for each person and clinicians should support patients and discuss their
values and preferences to reach a decision. Decision aids may support people in reaching these decisions
For clinicians We recognize that different choices may be appropriate for individual patients. Clinicians should support each
patient in reaching a management decision consistent with his or her values and preferences. Decision aids
may support individuals in reaching such decisions
For policy makers and developers of
quality measures
Policy-making will require substantial debate and involvement of various stakeholders. An appropriately
documented decision making process could be used as quality indicator
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